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Microfluidic devices for the simultaneous characterization of insulin release from 
four and 15 isolated pancreatic islets were developed.  Quantification of released insulin 
from islet samples was performed using parallel immunoassays coupled to capillary 
electrophoresis with fluorescence detection.  Assays for insulin were completed in a 
serial fashion on each channel every 6 – 10 s, giving fast temporal resolution used for 
investigations into insulin secretion dynamics.  Assay limits of detection were between 
0.5 – 10 nM insulin. 
 Individual islets were housed on the chips while perfusion streams carrying 
glucose or other secretagogues were used to induce insulin release.  Secreted insulin was 
then mixed with fluorescently-labeled insulin and anti-insulin antibody in reaction 
channels for a competitive immunoassay.  Portions of the continuously flowing reaction 
streams were injected onto separation channels where bound fluorescent insulin:antibody 
and free fluorescent insulin complexes were separated electrophoretically and detected 
via fluorescence.  Relative amounts of these products were used to determine the amount 
of released insulin. 
 The 15-islet microchip was used to investigate possible roles of leptin signaling 
on insulin secretion.  Through a collaborative effort, islets from mice lacking leptin 
receptors only in the pancreas were compared to control islets through insulin release 
xiv 
 
studies.  Specifically, the effects of leptin, glibenclamide, glucagon-like peptide-1, and 
palmitic acid on glucose-stimulated insulin secretion were investigated.  It was observed 
that leptin produces an inhibitory effect on insulin release and that lack of leptin signaling 
in islets enhances insulin release stimulated with glucose. 
 Modifications were made to the 15-islet chip to ensure more uniform sampling of 
insulin from islets.  The new islet sampling method was used to characterize oscillatory 
insulin release under various conditions.  It was found that when treated appropriately, 
islets from individual mice displayed similar insulin secretion and Ca2+ flux oscillation 
frequencies.  These frequencies were shown to be different from mouse to mouse, 
complementing previous studies.  Additionally, the effects of free fatty acid-induced 
liptoxicity on pulsatile insulin release were investigated.  Results from these experiments 










 The development towards lab-on-a-chip devices has been greatly advanced since 
the first introduction of microfluidics for chemical analysis,
1,2
 with much progress being 
made in the area of chemical separations.
3-6
  The attractiveness of microfluidics-based 
separations to analytical chemists owes to its ability to routinely perform rapid and 
sensitive experiments on a small footprint with minimal use of sample and reagents.  
Additionally, microfluidic technology facilitates the fabrication of devices with integrated 
functions,
7-9
 an advantage which has led to a multitude of microdevices for pertinent 
biochemical assays.  The success of microchips in basic research has led to the birth of 
specialized commercial devices for multiple bioanalytical applications.
10-12
  It is clear that 
recent advancements made with these tools have placed the use of microchips on the 
frontier of research in cell biology, genetics, pharmacology, and other biomedical fields. 
 Many advances with microfluidic devices highlighted above were demonstrated 
on “single-sample” chips capable of performing only one analysis at a time.  An 
additional advantage of microfluidics is the ease of fabricating several analysis manifolds 
on a single device, thus potentially increasing throughput while keeping the cost of 
fabrication essentially the same.  Research using such parallel separations will help to 
realize the continued advancement of microdevices used for real-world applications. 
2 
 
 Advances in high-throughput techniques have already shown importance to many 





 and DNA analysis.
15
  Clearly, the time and cost savings that these 
high-throughput methods offer can be increased by utilizing the short analysis times and 
small reagent volumes associated with micro-scale systems.  However, several challenges 
in developing parallel analysis microchips must be overcome.  These challenges include: 
(i) organizing multiple channel networks on a single device with a small footprint, (ii) 
coupling multiplexed chips to peripheral equipment (e.g. power supplies, pumping 
devices), (iii) developing multi-channel detection methods, and (iv) achieving 
reproducible analyses across parallel channels. 
 Over the past decade, we have seen the addressing of these concerns with 
numerous reports of parallel separations on microchips.  The majority of this introduction 
will serve as a brief review of recent technological advances towards realizing high-
throughput microfluidic devices using parallel separations.  Though microchip channel 
organization and operation are critical to performance, design details are commonly 
influenced by chosen parallel detection methods.  As detection is a crucial part of 
performing parallel separations on microchips, a discussion of various methods of 
multiplexed detection, consisting mainly of fluorescence techniques, will precede review 
of recently developed microchips for parallel analysis of biomolecules, affinity assays, 






Multiplexed Detection Methods 
 One important aspect considered in the development of a microfluidic system 
with multiple separation channels is how detection will be performed because most 
detectors are designed for single point detection.  Although there have been a multitude 
of reports using single separation microchips and detectors for measuring low quantities 
of analyte,
16,17
 the development of a multi-channel instrument capable of highly sensitive 
detection of numerous channels is challenging.  Several research groups have developed 
specialized detectors for use with their own custom-designed microchips that use specific 
technology providing either high sensitivity, high sampling rates, or ease of use.  In broad 
terms, three basic methods of detecting simultaneous separations on multiple channels 
have been utilized: i) moving a single point detector across the chip at a frequency high 
enough to adequately detect separated bands in each channel (e.g. scanning laser-induced 
fluorescence (LIF)), ii) having a single detector that can continuously monitor all 
separations while maintaining channel-to-channel resolution (e.g. fluorescence imaging), 
and iii) assigning independent detectors to each channel on the device (e.g. parallel 
electrochemical detection). 
 Scanning LIF.  Fluorescence detection is commonly used with microchips owing 
to its high sensitivity and ease of use with micrometer-dimensioned channels.
18
  Lasers 
are commonly used for excitation on these devices; however, coupling laser excitation to 
multiple detection points has been a challenge requiring unique solutions.  Rather than 
using multiple stationary laser spots for excitation, requiring many complicated optical 
alignments to be made for proper excitation and detection, the majority of research has 
focused on scanning a single laser spot across several channels.  Numerous methods of 
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scanning LIF detection have been demonstrated, ranging from relatively simple stage 
translation devices for use with a stationary laser to detectors based on a mobile objective 
lens. 
 Translation Stage.  The basis of translation stage-driven multiplexed LIF 
detection is moving a microchip over a fixed detection point so that the multiple channels 
on a device can be sampled.  The advantage in using this approach is that detection can 
be performed on parallel aligned channels without moving any components of the optical 
train.  The first reported scanner of this type, albeit not used for detection with 
microchips, was reported as an approach to high-throughput DNA sequencing using 
capillary array electrophoresis (CAE).
19
  This same stage translation detection scheme 
was later demonstrated for use with parallel separation chips.
20
  In this report, the 
translation stage detector was used for monitoring multiple DNA separations on a chip 
with 14 parallel channels (12 channels for separations and two for optical alignment).  
Parallel epi-fluorescence detection was performed using a stationary 20x objective lens 
while scanning the microchip a distance of 1.2 mm at a speed of 1.0 cm s
-1
, allowing an 
overall sampling rate of 3.3 Hz. 
 A more recent study also shows the use of stage translation for fluorescence 
detection of parallel capillary electrophoresis (CE) separations.
21
  In this report, the 
advantage of having a non-moving optical train has been exploited to facilitate optical 
gating for sample introduction in parallel channels.  Optical gating, previously shown to 
be compatible with microchips in a study performed by this same group,
22
 uses high 
intensity laser light to continuously photobleach sample flowing though a separation 
channel.  An analysis is made by temporarily blocking the laser and letting a fluorescent 
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sample plug separate by CE.  Experiments were performed by scanning a five-channel 
CE microchip across two laser spots (gating and probe beams) which were offset by 400 
μm to allow simultaneous detection on one channel and gating on another.  A voice coil 
actuator, which can provide accurate placement from micrometer to centimeter distances, 
was used to drive the translation stage.  It was found that moving the stage at a frequency 
of greater than 10 Hz produced significant vibrations that increased experimental noise, 
illustrating a drawback of using this detector for monitoring fast separations. 
 Scanning Mirror.  As translation stage detectors cannot offer the needed speed 
for detection of fast parallel separations, a drive towards the development of faster 
scanning detectors led to coupling mirror-based laser scanning with microchip 
separations.  Unlike translation stages, scanning mirror systems raster a laser spot across 
channels on a stationary chip.  The use of galvo-mirrors for scanning laser spots across a 
short distance has been previously demonstrated by many commercial scanning confocal 
imaging systems.
23
  Some of the scanning mirrors used in these instruments can scan at 
kHz frequencies, holding potential for improvement over the approximate 10 Hz limit of 
translation stage detection.  However, mirror-driven parallel detection on microchips with 
kHz rates has yet to be demonstrated. 
The earliest mirror-driven laser scanning detectors were built for monitoring 
simultaneous DNA separations.
24,25
  One study gives a brief description of the laser 
scanning device, stating that a 5-μm laser spot was scanned across a 48 channel 
microchip (a distance of 7.4 mm) at rate of 40 Hz.
24
  Fluorescence was collected through 
a stationary objective and detected with a PMT to generate 16-bit images from which 
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parallel electropherograms were extracted.  The reported limit of detection (LOD) using 
this detector was 1 molecule Cy3 dye per 100 μm
2
. 
Details of another homemade mirror-based scanning detector were described in a 
later study.
26
  Juxtaposing the previous galvo-mirror detector that was described as 
scanning at a constant rate across a microchip, the mirror used in this study behaved 
similarly to a stepping motor allowing fast transitions between channels and longer 
integration times for a single detection point.  This laser scanning technique is 
advantageous as it increases the duty cycle of the detector yielding higher sensitivity 
detection.  A specific duty cycle of 71% was reported for this detector when scanning 
over an eight-channel microchip (six channels for separations, two for alignment) at a 
rate of 7.1 Hz for each channel.  An LOD of 30 pM fluorescein was reported using this 
detector. 
 Acousto-optical Deflection.  Though mirror scanning detectors can achieve high 
sampling rates and increased duty cycles, they are still mechanically dependent on 
moving parts.  The use of any mechanically controlled scanner is going to inhibit 
achieving ultrafast scanning rates due to issues with mechanical noise and the distortion 
of signal.
27
  The Landers group has done much work
27-29
 towards eliminating the need for 
mechanically controlled instrumentation in parallel microchip detectors by employing 
laser scanning technology based on acousto-optical deflection (AOD).  The principles of 
AOD are centered on laser light diffracting though an optically transparent medium at an 
angle that is dependent upon both the wavelength of light and the frequency of acoustic 
waves traveling though the device.  The angle of light diffraction can be changed by 
manipulating the acoustic wave frequency via a piezoelectric transducer.  The advantage 
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of using such a device for laser scanning includes the elimination of mechanical noise 
while achieving fast scan rates (kHz range).  The developed detector has been used with a 
variety of microchips with an on-chip scanning distance of up to 2.4 cm, longer than the 
highest reported mirror-driven chip scanning distance of 10 mm.  Figure 1.1 shows a 
series of CCD images illustrating the scanning of a laser spot across an eight-channel 
chip.  For these studies, fluorescence emission from sample bands was collected though a 
non-moving objective directed onto a PMT.  An additional advantage in using this 
method of laser scanning is the ability to randomly address microchannels with channel-
to-channel transition times down to 11.3 μs.  One disadvantage, however, is that the 
diffraction of light through this device is wavelength dependent, making descanning and 










Figure 1.1. Six CCD images showing the positioning of a laser spot (white dot in the images) scanned 
across eight microfluidic channels using AOD.  For this laser scanning technique, the laser passes 
through an optically transparent diffractive medium before reaching the chip surface.  The angle of 
diffraction through the medium can be controlled by applying acoustic waves to the device.  Altering 
the frequency of acoustic waves changes the angle of light diffraction, thus allowing accurate 
positioning and scanning of a laser spot across parallel running channels.  This type of laser scanner 
was used to monitor parallel separations on a microchip, however, detection was performed with a 
PMT rather than CCD imaging as shown.  Reproduced from reference 27. 
 
 
Rotary Confocal.  Attempts to maximize the number of microfluidic channels 
fabricated on a single device have led to the exploration of new channel organization 
methods.  One design that has been proven useful for the arrangement of hundreds of 
channels on a single device is the radial alignment of separation channels in which fluidic 
reservoirs are situated close to the outside edge of a circular chip and separation channels 
converge to a common waste reservoir in the center.  The Mathies group, responsible for 
the introduction of this parallel network design, has also developed a detector suitable for 
use with radially aligned channels.
30
  Detection with this device, continually improved 
upon to allow use with higher channel densities from 96 to 384,
31,32
 is based on rotating 
an objective lens around an off-center axis for laser-excited confocal fluorescence in a 
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circular path.  For this device, the larger mechanically-based movements of the optical 
train have allowed dramatic increases in the number of channels on which detection can 
be performed.  The detector uses a hollow stepping motor shaft with a rhombic prism and 
objective lens placed atop to allow displacement of laser light traveling up a vertical axis 
(orthogonal to the microchip surface) by 1 cm.  The prism and objective are then rotated 
resulting in a scanning path of a 2 cm diameter circle.  Fluorescence is collected though 
the same objective and directed towards a four-color confocal detector.  It has been 
reported that sampling frequencies as high as 20 Hz can be used with a spatial resolution 
of ~12.6 μm, however, lower rotational speed is typically reported for experiments with 
this detector.  LODs as low as ~1 pM (S/N = 2) have been reported using this device. 
 Fluorescence Imaging Detectors.  CCDs and other imaging detectors have been 
used in conjunction with the scanning laser instruments featured above; however, mostly 
for the purpose of detector characterization and alignment rather than for detection in 
actual separation experiments.  In cases when highly sensitive detection is not required, it 
may be advantageous to use an imaging detector due to the near 100% duty cycle 
capabilities, commercial availability, lack of moving parts, and relative ease of use.  
Indeed, parallel fluorescence detection of multiple separations on a microchip has been 
performed on standard commercially available fluorescence microscopes using arc lamp 
excitation and CCD camera detection.
33,34
  Commercially available CCD cameras attain 
frame collection rates up to hundreds of frames per second making them useful for 
detection of fast separations.  Additionally, the use of commercial imaging detectors 
requires little optical alignment.  Disadvantages of an imaging detector include the risk of 
channel crosstalk (controlled by proximity of channels in the detection region and image 
10 
 
resolution) and a defined imaging area that may be difficult to manipulate if a specific 
image magnification is required. 
 Several groups have demonstrated laser-induced excitation with CCD detection.
35-
39
  In these studies, laser light was shaped into a line using a cylindrical lens and directed 
across all sample channels on a chip, exciting sample plugs passing through it.  Laser 
light was directed at an angle (typically around 45°) towards the chip surface while 
fluorescence was collected through perpendicular optics that focused an image of the 
detection region onto a CCD chip.  Parallel separation data were then produced by 
plotting fluorescence intensities versus time from several regions of the images that 
corresponded to microfluidic channels.  This detection scheme was used to monitor up to 
10 parallel channels with a sampling frequency of 30 Hz.
36
  An interesting modified 
version of this detector was demonstrated by a system that positioned a laser directed 
across parallel channels though the side of the microchip (perpendicular and in the same 
plane as channels).
40
  Imaging detection from 48 samples across a 140 mm width was 
completed with a CCD. 
 Electrochemical Detection.  Electrochemical detection is another method for 
monitoring separations that has been used for parallel analysis on microchips owing to 
the ease of microfabricating detection electrodes on the same scale as microchannels.  
Although detection limits are not as low as have been achieved with fluorescence 
detection, electrochemical monitoring does offer reasonable LODs while requiring 
relatively simple instrumental setups.  Electrochemical detection for parallel microchips 
has recently been demonstrated.
41
  In this study, parallel electrochemical detection was 
performed with a contact conductivity array used to monitor simultaneous separations 
11 
 
performed in 16 channels on a microchip.  In contrast to other electrochemical techniques 
such as amperometry, conductivity detection does not require the analyte to be 
electroactive,
42
 suggesting that this device can be used with a wide variety of native 
samples.  Detection at each channel was controlled by independent pairs of 
microfabricated gold electrodes (60 μm wide with a 5 μm space) and electrical circuits 
(16 circuits in total).  Parallel separations were monitored using a bipolar pulse voltage 
waveform with an amplitude of ±0.6 V and frequency of 6 kHz.  An image of the system 
is shown in Figure 1.2A.  LODs as low as 1.6 μM were reported from using this detector 






Figure 1.2. (A) Illustration of a workstation consisting of a microfluidic chip, chip holder, and 
necessary electrical connection devices for parallel CE separations and electrochemical detection.  
The device, fabricated from polycarbonate, allowed 16 parallel separations of amino acids, peptides, 
proteins, and DNA fragments. Electropherograms, staggered for clarity, are shown in (B).  (B) CZE 
separations of amino acids, peptides, and proteins are shown in channels 1 – 4 (bottom 4 
separations), channels 5 – 8, and channels 9 – 12, respectively.  Channels 13 – 16 (top four) were used 
for CEC separations of oligonucleotides.  Separations of all sample types were performed 
simultaneously.  Reproduced from reference 41. 
 
Parallel Microchip Applications 
 The multi-channel detectors reviewed have been used with a wide variety of 
parallel microchips, with most applications involving parallel chemical separations.  
Specific designs of parallel microchips have ranged from simple arrays of CE channels to 
more complicated systems including devices for parallel single cell lysing and 
separation
43
 and on-chip PCR coupled to CE analysis.
44
  This section will highlight 
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advances towards microchips for parallel separations of biomolecules, affinity assays, 
and DNA analysis. 
 Separation of Biomolecules.  One of the earliest examples of parallel amino acid 
separations on a microchip was performed on the previously described optical gating 
translation stage multiplexed detector.
21,45
  The nature of optical gating allowed chip 
designs to consist of parallel-aligned straight channels with no integrated injectors.  In 
these studies, parallel separations of NBD-labeled amino acids (arginine, phenylalanine, 
glycine, and glutamic acid) were performed on a five-channel microchip with a 750 V 
cm
-1
 field strength and 5 mm separation distance.  Reported detection limits for these 
separations were 1 mM, 500 μM, 500 μM, and 3.3 mM for arginine, phenylalanine, 
glycine, and glutamic acid, respectively.  Additionally, parallel separation of DNA 
fragments was performed by this group using a similar chip design and detector.
45
 
Another microchip for parallel CE separations of biomolecules has been reported 
more recently.
46
  This chip, while performing separations on only four parallel channels, 
required a more complicated design to allow for electrokinetic injections to be made 
using four single-tee injectors.  Injections and separations on a single device were 
controlled by a high voltage power supply consisting of six high voltage modules and 12 
high voltage relays.  This study reported separations of FITC-labeled glycine, arginine, 
phenylalanine, and lysine in a separation field of 400 V cm
-1
 over a distance of 40 mm.  
The same chip was used to separate myoglobulin, ovalbumin, BSA, and conalbumin 
using similar experimental procedures (same separation field and distance).  In an 






 Further increasing the number of parallel separations of biomolecules performed 
on a single device, a 16-channel polycarbonate chip has been used to separate amino 
acids, peptides, proteins, and DNA fragments in a single experiment.
41
  The 16 channels 
on the device were arranged into eight pairs of independent channels, allowing 
simultaneous separations of multiple sample types to be performed with relatively 
different experimental conditions.  The chip performance was evaluated by performing 
CZE analysis of amino acids (alanine, valine, glutamine, tryptophan), peptides (leucine 
enkephalin, methionine enkephalin, oxytocin), and proteins (chymotrypsinogen A, 
cytochrome C, BSA) and CEC separations of an oligonucleotide ladder.  
Electropherograms from these separations are illustrated in Figure 1.2B.  Separations of 
all analytes were completed in less than 4 minutes in a field of 90 V cm
-1
 yielding 
detection limits as low as 7.1 μM, 1.6 μM, 3.3 μM, and 0.09 μg/μL for amino acids, 
peptides, proteins, and oligonucleotides, respectively. 
 Although it has been shown that radial organization of channels allows hundreds 
of parallel separations to be conducted on a single chip,
31
 the parallel organization of 
channels on a device can still be advantageous due to its compatibility with several 
detector types, ease of sample loading,
41
 and simple design that facilitates integrated 
electrodes for CE control.  The latter advantage was demonstrated through a device that 
used a unique 12-channel parallel design for separations of DNA fragments.
34
  The chip 
used I-shaped microchannels fabricated in PDMS (tapered at the injection point to act as 
a passive stop valve) to perform injections of sample and CE separations in a channel 
with only two fluidic reservoirs.  The elimination of reservoirs used for sample injections 
facilitated the fabrication of parallel microchannels with integrated electrodes by 
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allowing the close proximity of parallel networks.  Functionality of the device was tested 
by performing parallel separations of 10 fragments of a 100 – 1000 bp DNA ladder. 
 Affinity Assays.  The versatile organization of channel layouts offered by 
microfluidics makes the technique attractive for use with biochemical and affinity assays.  
For this reason, microchips have been frequently used in studies of protein and enzyme 
interactions.
47
  Though microchips offer an increase in analysis speed for a single sample, 
the overall speed of multiple assay completion on a single sample device is still lower 
compared to the multiplexing abilities of standard larger-scale methods such as plate-
readers or gels with multiple lanes.  The creation of microdevices for parallel affinity 
assays increases the overall throughput of homogeneous assays in microchip format, 
making rate of completion comparable with standard assay techniques. 
 Immunoassays.  The first microfluidic device for the parallel completion of CE-
based immunoassays was characterized with direct assays for ovalbumin and anti-
estradiol.
26
  The device, illustrated in Figure 1.3, consisted of eight separate channel 
manifolds, two for detector alignment and six capable of supporting online mixing of 
immunoassay reagents and CE-LIF analysis.  Mixing of reagents, reaction, and separation 
of products was completed within 60 s for all experiments and within 30 s in optimized 
conditions, demonstrating the potential of high-speed parallel immunoassays on a chip.  
Detection was performed with a scanning LIF instrument built in-house.  The chip was 
used to demonstrate both simultaneous immunoassays of a single sample and 
simultaneous calibration and analysis in a single experiment, allowing a complete 
calibrated assay to be performed within 30 s.  Detection limits reported for an anti-
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estradiol assay were 4.3 nM in any single channel and 6.4 nM for the cross-channel 
calibration mode. 
 
Figure 1.3. Illustration of a microchip design for six simultaneous CE-based immunoassays.  Each of 
six channel manifolds on the device is capable of online mixing of immunoassay reagents (lower right 
expansion) from reservoirs S1 and S2.  Additional fluidic reservoirs shown in the figure include 
running buffer (B), sample waste (SW), and buffer waste (BW).  After mixing, portions of the 
immunoassay mixtures were then injected onto parallel CE separation channels using a double-tee 
injector (lower left expansion).  Parallel CE separations of the immunoassay mixture were performed 
on multiple separation channels arranged parallel (upper right expansion) before passing through 
the detection point.  The most outer two channels were used for optical alignment of detection 
equipment.  The device was used for assays of ovalbumin and anti-estradiol.  Reproduced from 
reference 26. 
 
A dramatic increase in the number of simultaneous CE-based immunoassays 
performed on a microchip was demonstrated with a 48-channel device.
48
  While offering 
an increased rate of immunoassay product separation and detection, this device was 
comprised of only electrophoretic injection and separation channels and lacked the ability 
for on-chip mixing of reagents and calibration.  Sample preparation was performed 
completely off-chip and consisted of a 45 minute incubated reaction.  The chip was used 
for a TNT assay with a reported 1 ng mL
-1





 A recently developed chip has demonstrated the use of parallel immunoassays for 
the monitoring of cellular secretions from multiple independent biological samples 
housed on the device.
49
  With this device, insulin secretion was continuously sampled 
from four separate pancreatic islets and quantified every 6.25 s using online mixing and 
reacting of immunoassay reagents coupled to parallel CE-LIF analysis.  Over 700 assays 
were completed in a 20 min experiment, noting a significant decrease in immunoassay 
reagent costs compared to typical insulin ELISA kits.  Parallel fluorescence detection was 
performed using a commercial scanning confocal microscope operated in line scan mode.  
An LOD for insulin was reported as 7 nM. 
Additional parallel immunoassays, though not utilizing CE, have been developed 
for sandwich-based assays.
50,51
  One report examined a polymer CD-shaped chip that 
utilized centrifugal force for mixing and dispensing immunoassay reagents in precisely 
defined volumes.
50
  The chip, when rotated at sufficient speed, would introduce solutions 
of biotinylated antibodies against a target molecule into 104 parallel on-chip 
microcolumns packed with streptavidin-coated particles.  Solutions of sample and then 
fluorescently labeled detection antibody were then introduced in a similar manner after 
which fluorescence of the packed beds was used to determine sample binding.  Assays 
for α-fetoprotein, interleukin-6, and carcinoembryonic antigen with reported LODs of 
0.15, 1.25, and 1.31 pM, respectively, were performed at speeds up to 104 immunoassays 
in 50 min. 
 Enzyme Assays.  A parallel microchip for enzyme assays was reported
52
 that 
used a similar chip design and translation stage optical gating detector from previous 
work.
21,45
  To monitor multiple enzymatic reactions, continuous serial injections of an 
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enzyme/substrate mixture were made into parallel microchannels for CE-LIF analyses.  
The chip was used for monitoring the hydrolysis of fluorescein mono-β-D-
galactopyranoside (FMG) by β-galactosidase (β-Gal) with and without phenylethyl β-D-
thio-galactoside (PETG), a competitive inhibitor.  The separation of enzyme reaction 
products was performed in a separation field of 500 V cm
-1
 with 30 s temporal resolution.  
Results from the parallel studies were used to calculate Km values from Lineweaver-Burk 
plots.  Additionally, the simultaneous monitoring of the hydrolysis of FMG with different 
inhibitors (no inhibitor, lactose, and PETG) was performed by testing each inhibitor on a 
different channel.  The results from this study illustrate the potential for microfluidics-
based high-throughput screening of drug candidates for potential activity. 
 Recently, microchips with 16 and 32 parallel electrophoresis units were used to 
investigate G protein GTPase activity.
53
  Utility of the 16-channel design was 
demonstrated by extracting kinetic information from serial assays performed in parallel 
every 20 s.  The 32-channel design was used at a slightly lower temporal resolution 
(assays every 30 s), but still allowed an overall throughput of 4,320 assays per hour.  
Separations on both devices were reproducible showing normalized peak area RSDs of 
5% and 11% for the 16-channel and 32-channel devices, respectively. 
 DNA Analysis and Integrated Devices.  To address the needs of the human 
genome project, many researchers strived for the development of methods to improve the 
speed, cost-effectiveness, and throughput of DNA sequencing.
54
  The developments of 
capillary array gel electrophoresis have offered techniques equaling the high-number 
DNA sample processing capabilities of conventional slab gel electrophoresis, making it 
commonly used for DNA analysis.  Owing to the simple, low cost fabrication of 
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microfluidic devices and potential for high speed separations, it has not been surprising to 
see rapid development of microchips for parallel DNA separations and sequencing.  The 
capabilities of the first parallel chip for DNA analysis were tested by performing 12 
simultaneous separations of pBR322 DNA samples and also by genotyping HLA-H.
20
  
While this device was not able to provide higher throughput than the current CAE 
techniques, it demonstrated potential for multiplexed genetic analysis on chips. 
 The ease of fabricating parallel channels in microfluidic devices has allowed rapid 
improvements to this 12-channel design to be made over the past decade.  There are 
several reviews available that include a discussion on the development of these 
devices.
32,54-56
  The Mathies group has pioneered much progress towards high-throughput 






 devices for 
DNA separations.  The development of these chips was a significant advancement as the 
throughput of DNA microdevices was improved while the cost of fabrication did not 
increase substantially.  Potential applications of parallel DNA chips have been 





 and short tandem repeat typing.
61
 
Additionally, a recent paper has reported a system with 768 parallel channels for 
high throughput DNA sequencing.
62
  This system consisted of two 25 cm x 50 cm 
microfabricated plates, one illustrated in Figure 1.4, with 384 separation channels each.  
Analysis was performed on an automated custom-built instrument for sample loading, 
separation, detection, and plate regeneration (one plate was prepared for experiments 
while another was used for analysis).  A scanning epi-fluorescence detector rotating at 3 
Hz, compatible with the 384 lanes of a single chip, was used for single plate detection.  
20 
 
Once the separations were completed on one chip, the laser was then relocated to the 
adjacent chip for a second analysis. 
 
Figure 1.4. One of two microfabricated plates used in a 768-lane system for DNA sequencing.  Each 
plate consists of 384 parallel channels for separations, with the spacing between channels narrowing 
upon reaching the anode to facilitate scanning laser detection.  Separation and detection was 
performed on one plate while another was prepared for experimentation.  On this chip, 384 samples 
were loaded into laser-drilled access ports arranged into eight rows (each containing 48 cross 
injectors), illustrated by the expansions in the figure.  Fluidic reservoirs for the device were 
fabricated using a fiberglass board that was affixed to the plate.  Reproduced from reference 62. 
 
 
 While these devices show unprecedented capabilities for performing hundreds of 
separations simultaneously, they are comprised of only simple injection and separation 
channels and have no other integrated function capabilities.  Recent advances in 
integrated parallel DNA analysis on microchips include devices for PCR amplification of 
samples and CE separations.
44,63
  On these chips, precise temperature of four parallel 
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nanoliter sized PCR chambers was controlled with resistance temperature detectors and 
heaters integrated into the devices.  Flow through these chambers and onto separation 
channels were controlled by PDMS valves.  Though these reports present a down-sizing 
of the number of parallel analyses compared to previous DNA microchips, there exists 
potential for an increase in throughput through the addition of microchannel networks 
and heating elements. 
 Concluding Remarks on Parallel Microchips.  The research devoted to 
developing lab-on-a-chip devices for multiplexed analysis along with complimentary 
detection instrumentation has yielded a number of exceptional systems that exemplify the 
potential for their widespread use.  Work towards this goal is still needed; however, 
preliminary success in this field has shown outstanding results.  Widespread use of 
parallel microchips is beginning to be realized through the commercial development of 
high-throughput microdevices by several companies.  Future work in this direction 
should focus on the integration of sensitive detectors on parallel analysis chips, 
eliminating the need for specialized instrumentation and facilitating portability and use in 
clinical, environmental, and research lab locations.  The advancements outlined in this 
chapter lead the way for a greater transition from microchips being used only in basic 
research labs to their specialized design and use for real-world situations. 
 
Analysis of Living Cells on Microfluidic Chips 
The ability to create devices for performing sophisticated physiological 
experiments on cells has made the use of microfluidic chips attractive for the analysis of 
biological samples.  The first microchips developed specifically for cellular studies 
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  Analysis of cellular components with 
these devices could be performed with on-chip cell lysing.
68,69
  Later, the development of 
cell trapping and perfusion methods for maintaining cell viability allowed the on-chip 
culturing of samples for long-term analysis.
70,71
  Many of these devices made use of 
advances in fabrication technology that allowed decreases in microchip volumes.  Small 
channel volumes compatible with the sizes of cells allow for rapid exchange of cell media 
and reagents, which can be critical in experiments requiring fast stimulation and 
monitoring of cells. 
Recent work in developing microdevices for the analysis of cells has produced a 
number of devices for examining cellular physiology.  The ease of fabricating and 
integrating electrodes into microchips has allowed the creation of chips for 
electrophysiological patch clamp experiments
72,73
 as well as electrochemical detection of 
cellular secretions.
74
  Microfluidic substrates are commonly optically transparent (e.g., 
glass or PDMS) allowing cells trapped on a chip can be probed by spectroscopic 
methods, for example, using Ca
2+





Recently, the ability to design elaborate microchannel networks has been used to produce 
a device for high throughput screening of cell-cell communication in an array format.
76
  
These examples show various microchip techniques used for the analysis of cells and 
demonstrate the versatility afforded by microfluidic tools for studying a variety of 






Pancreatic Islets of Langerhans 
 The endocrine pancreas, responsible for producing and secreting hormones 
controlling blood glucose levels,
77
 is made up of clusters of 2,000 – 4,000 cells known as 
islets of Langerhans.  The cells that comprise islets are classified by their hormonal 
component: α-cells, producing glucagon; β-cells, producing insulin; δ-cells, producing 
somatostatin; and PP cells, producing pancreatic polypeptide.
78
  Insulin released from 
islets is a primary regulator of fuel metabolism promoting glucose uptake by target 
tissues and storage of this fuel as glycogen.
79
  Dysfunction of islets, causing decreased 
insulin production and secretion as well as impaired glucose sensing and cell turnover,
80
 
can lead to lost control of blood glucose levels and development toward the disease 
diabetes. 
 Diabetes mellitus, a disease characterized by hyperglycemia, affects 23.6 million 
people in the U.S. alone.
81
  There are two major classes of diabetes: type 1, characterized 
by autoimmune destruction of β-cells and type 2, characterized by insulin resistance of 
target tissues and the inability of islets to overcome this resistance with sufficient insulin 
secretion.
82
  Typical treatments for the disease include administration of insulin as well as 
drugs that stimulate insulin release from existing islets or treat insulin resistance; 






 and islet 
transplantation
86
 have also been gaining attention. 
The development of new treatments for diabetes is facilitated by research into the 
underlying causes of the disease, often requiring methods for measuring insulin release 
from islets.  In typical batch islet experiments, groups of islets are perfused with an 
insulin secretagogue after which fractions of perfusate are collected and analyzed for 
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insulin content.  Analysis of single islet secretion has been performed using similar 
techniques;
87
 however, the offline nature of fraction analysis makes these methods time 
and labor consuming and not amenable for certain applications.  For example, 
characterization of islets for transplantation requires rapid determination of islet health 
before implantation into a patient.
88
  Additionally, batch islet experiments hamper the 
ability to measure secretion kinetics on the single islet level since groups of islets may 
have varying secretion phases. 
Tools for rapid analysis of insulin release from single islets have been 
developed.
89,90
  The rapid nature of these methods owes to using an electrophoresis-based 
immunoassay for insulin,
91
 allowing solution-phase mixing of immunoassay reagents for 
favorable kinetics.  In this assay, solutions of fluorescently-tagged insulin, anti-insulin 
antibody, and sampled insulin are mixed and allowed to react after which the formation 
of immunoassay products is measured by CE-LIF.  Recent advances in these tools have 
made use of microfluidics for quantitative insulin release measurements from single 
islets.
92,93
  However, the single-sample nature of these devices makes throughput lower 
than conventional batch islet perfusion techniques, and thus not amenable for research 
requiring large sample sets.  Research presented in this dissertation is aimed at the 
development of microchips for parallel analysis of single islets capable of producing high 
throughput data that can be used to analyze single islet secretion dynamics was well as 







 Chapter 2 describes the development of a microfluidic chip for monitoring insulin 
release from four isolated pancreatic islets in parallel.  The device uses parallel CE-based 
immunoassays to quantify insulin release from islets, a technique previously developed in 
our lab.  On the chip, multiplexed fluorescence detection of parallel aligned separation 
channels was performed using a scanning confocal microscope operated in line scan 
mode.  Insulin monitoring ability was demonstrated by characterizing secretions from 
islets stimulated with a step change glucose concentration (3 mM to 11 mM).  Data and 
results from this chapter were originally published in Analytical Chemistry.
49
 
 Chapter 3 presents a further multiplexed islet secretion monitoring chip, capable 
of analyzing 15 islets simultaneously.  The developed chip made use of a radial 
alignment of microfluidic networks in which CE separation channels converged at a 
common point for multiplexed detection via fluorescence imaging.  The outer portion of 
the chip was used for islet housing and mixing of immunoassay reagents.  The chip was 
used to successfully characterize glucose-stimulated insulin release from 15 islets in 
parallel. 
 Results from a study investigating the effects of leptin signaling on insulin release 
using the 15-sample device are presented in Chapter 4.  This work was done in 
collaboration with Dr. Rohit N. Kulkarni and Dr. Tomoaki Morioka of the Joslin 
Diabetes Center at Harvard Medical School who developed a pancreas-specific leptin 
receptor knockout mouse model.  Work performed by the author was limited to testing 
single islets for insulin release under various conditions.  Data presented in this chapter 
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were either originally published in The Journal of Clinical Investigation
94
 or are in 
preparation for submission. 
 Chapter 5 deals with improving the insulin sampling portion of the 15-islet 
microchip to allow more uniform sampling of islet secretions.  Fluid flow through the 
improved microchip was characterized, and data showing biphasic and pulsatile insulin 
release from single islets is presented.  This chapter includes results from preliminary 
investigations into pulsatile insulin release properties including: i) characterization of 
oscillatory secretion frequencies of islets from individual animals and ii) studying the 
effects of chronic free fatty acid exposure on oscillatory insulin secretion.  Results 






SERIAL IMMUNOASSAYS IN PARALLEL ON A MICROFLUIDIC CHIP FOR 





Microfluidics offers a versatile platform for growing, manipulating, monitoring, 
and analyzing cells because it enables precise control of cellular environment, 
automation, and integration of analytical functions.  Microfluidic devices have been used 
for analyzing both lysed cells
69,95,96
 and for monitoring activity of living cells.  Examples 





 and the capture and chemical activation of single cells.
99
   
Pancreatic islets, which comprise the endocrine portion of the pancreas, are cell 
clusters that contain 2,000-4,000 cells each and control blood glucose levels through 
secretion of the peptide hormones glucagon and insulin.
100
  The secretion of insulin from 
an islet is regulated primarily by the metabolism of glucose.
101
  Exposing islets to step 
increases in glucose concentration initiates complex insulin release dynamics consisting 
of a “first phase” burst of insulin secretion followed in a few minutes by a “second 
phase” of sustained lower rate of release.
102,103
  Impaired glucose-stimulated insulin 
release is a hallmark of type 2 diabetes;
104
 therefore, considerable effort is devoted to 
studying characteristics of insulin secretion to better understand the development of 
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this disease.  Most secretion studies are performed by using radioimmunoassay or ELISA 
to analyze insulin content in fractions collected from groups of islets.  Although 
powerful, these methods are cumbersome, expensive, and not amenable to high 
throughput experiments on single islets.  Because of these limitations and the importance 
of studying insulin release, improvements upon methods of insulin secretion 
measurement are of interest.   
Our lab has previously developed a microfluidic chip that can be used to monitor 
insulin secretion from single islets.
93
  In this device, cells on the chip are continuously 
perfused with physiological media or buffer.  A small fraction of the perfusate is 
continuously sampled by electroosmotic flow and assayed for insulin by serial 
electrophoresis-based competitive immunoassays.  Rapid chemical separations on the 
chip enable assays to be performed every few seconds, allowing the dynamics of 
secretion to be monitored.  The chip-based device was a useful advance because it 
automated the monitoring of secretion and provided sufficient sensitivity to allow 
detection at high temporal resolution from single islets.
92,93
  Indeed, the device has 
already been used to assay the effects of gene knockouts on insulin secretion.
105
  
Although this chip is high throughput in the sense that many immunoassays can be 
performed on a single biological entity, it only allows one sample to be monitored at a 
time. 
An additional advantage of using microfluidic techniques for investigation into 
biological systems is the facilitation in creating high throughput tools.  Microfluidic 














  The basic principle underlying these devices is the multiplexing 
of microfluidic channels or manifolds, each capable of analyzing an individual sample, 
on one microchip.  In this work, a new device will be described that allows serial 




 Chemicals and Reagents.   Fluorescein isothiocyanate-labeled insulin (FITC-ins) 
was purchased from Molecular Probes (Eugene, OR), and monoclonal antibody (Ab) to 
human insulin was from Biodesign International (Saco, ME).  Collagenase type XI, 
insulin, ethylenediaminetetraacetic acid (EDTA), and Tween 20 were purchased from 
Sigma (St. Louis, MO).  Tricine, electrophoresis grade, was from MP Biomedicals 
(Aurora, OH).  Cell culture reagents were obtained from Invitrogen (Carlsbad, CA).  All 
other chemicals were purchased from Fisher (Pittsburgh, PA).  All solutions were made 
using Milli-Q (Millipore, Bedford, MA) 18-MΩ deionized water and filtered using 0.2-
µm nylon syringe filters (Fisher).  Stock antibody solution was stored at 4 °C in the 
manufacturer-provided phosphate-buffered saline.  Stock FITC-ins was diluted to 166 
µM using the immunoassay reagent buffer and stored at -32 °C until use. 
Several different solutions were used as physiological, electrophoresis, and 
reagent buffers.  Balanced salt solution (BSS) consisted of 125 mM NaCl, 5.9 mM KCl, 
1.2 mM MgCl2, 2.4 mM CaCl2, 25 mM tricine, and 0.7 mg mL
-1
 bovine serum albumin 
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(BSA), adjusted to pH 7.4.  Immunoassay reagent buffer consisted of 50 mM NaCl, 1 
mM EDTA, 20 mM tricine, 0.1% (w/v) Tween 20, and 0.7 mg mL
-1
 BSA, adjusted to pH 
7.4.  Separation buffer consisted of 20 mM NaCl and 150 mM tricine, adjusted to pH 7.4. 
 Microfluidic Chip Fabrication and Preparation.   The developed microfluidic 
chip consists of four independent channel networks, each capable of performing online 
immunoassays.  The number of channel networks on the device was limited at four due to 
spatial restrictions (fluidic reservoir placement) and detection limitations (line scan 
distance), which are discussed later in more detail.  Figure 2.1 illustrates the layout for an 
individual microfluidic channel network and the entire parallel system.  The networks 
have equivalent electrical impedance (channels are of the same length) in order to 







Figure 2.1. Channel layout of a microfluidic device for monitoring insulin secretion from four islets.  
Each color indicates a single independent channel network. (A) A single fluidic network from the 
device.  Solid lines indicate microfluidic channels, and circles represent fluidic reservoirs and access 
holes to the channel networks.  Some features of the design have been exaggerated to help 
demonstrate chip function (e.g. spacing between separation and waste channels).  All channels were 9 
µm deep.  Operation of the chip is described in the Experimental Section. (B) The complete chip 
design (drawn to scale).  Shaded regions represent heating strips applied to underside of chip. (C) 
Close-up of the gating/detection region (not to scale).  All of the separation channels run parallel to 
each other, allowing for a scanning laser spot (path indicated by black arrows) to be used for LIF 
detection. 
 
The device was fabricated using a previously described method.
106
  Briefly, 76 
mm x 76 mm borofloat glass photomask blanks (0.7 mm thick) were purchased from 
Telic Co. (Santa Monica, CA).  Each blank had a 530 nm layer of AZ1518 positive 
photoresist on a 120 nm layer of chrome.  The blanks were exposed to UV light for 2 s at 
26 mW cm
-2
 through a custom-made photomask with the pattern shown in Figure 2.1B 
(Digidat, Pasadena, CA).  They were then exposed to AZ915 MIF photoresist developer 
(Clariant Corp., Summerville, NJ) and then CEP-200 chrome etchant (Microchrome 
Technologies, Inc., San Jose, CA).  The exposed glass regions were etched in 14:20:66 
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(v/v/v) HNO3/HF/H20 for 15 min resulting in 9 µm deep channels.  Channel access holes 
were drilled at the points indicated in Figure 2.1B with diamond-tipped 360 µm diameter 
drill bits (Tartan Tool Co., Troy, MI).  Piranha solution (3:1 v/v H2SO4/H2O2) was used 
to clean the etched blanks and cover plates, which were then exposed to RCA solution 
(5:1:1 v/v/v H2O/NH4OH/H2O2) for 40 min at 60 °C.  The etched and cover plates were 
sandwiched between two 3” diameter MACOR plates (Astro Met, Inc., Cincinnati,  OH), 
placed under a 400 g stainless steel mass, and bonded at 610 °C for 8 h in a Neytech 
Centurian Qex furnace (Pacific Combustion, Los Angeles, CA).  Once bonding was 
completed, microfluidic reservoirs (Upchurch Scientific, Oak Harbor, WA) were attached 
to the device over the access holes. 
Electrical connections to the 20 fluidic reservoirs were made with a chip-electrode 
interface built in-house.  Islet, Ab, and FITC-ins reservoirs were at ground.  Gate 
reservoirs were connected to either ground or a high-voltage power supply (CZE1000R, 
Spellman High Voltage Electronics, Hauppauge, NY) through a single high-voltage relay 
(Kilovac, Santa Barbara, CA).  Negative high voltage (-HV) reservoirs were connected to 
a single high-voltage power supply.  Two thin-film heating strips (Minco, Minneapolis, 
MN) attached to the underside of the chip allowed for the heating of all four islet 
reservoirs and reaction channels to 37 °C.  Heating of the chip was necessary in order to 
sustain islet health and decrease the time needed for the reacting of the immunoassay 
reagents.  Each perfusion inlet on the chip was connected via fused-silica capillary (150 
µm i.d., 360 µm o.d.) to a five-port manifold (Upchurch Scientific) and then to a 
reservoir containing perfusion solution pressurized with He to 170 kPa.  This system 
provided a flow of 0.6 µL min
-1
 into each islet reservoir. 
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Prior to daily use, chips were flushed with pressure-driven flow of deionized 
water by applying vacuum to the -HV reservoirs and then islet reservoirs for 5 min each 
(40 min total).  Chips were then conditioned by electroosmotically pumping 0.1 M NaOH 
through all channels followed by deionized water and then experimental solutions.  For 
this last step, FITC-ins and Ab (both 250 nM in immunoassay reagent buffer) were 
placed in the FITC-ins and Ab reservoirs, respectively.  Separation buffer was placed in 
the gate and -HV reservoirs.  For islet measurements, a single islet was placed in each 
drilled access hole in the islet reservoirs and perfused with BSS.  The flow in the 
perfusion system did not result in significant hydrodynamic flow throughout the channel 
network because the islet reservoir was open to atmosphere at the top of the chip, which 
allowed buffer from the perfusion inlet to exit the chip into a larger reservoir on the chip 
surface. 
Microfluidic Chip Operation.   The operation of the device is similar to that 
previously described for a single-islet immunoassay system.  To perform measurements,  
-5 kV was applied to the -HV reservoirs causing electroosmotic flow from the FITC-ins, 
Ab, and islet reservoirs into the reaction channel where immunocomplexes were formed.  
With the gate reservoirs at ground, the flow from the reaction channels was normally 
diverted to waste.  Actuation of the high-voltage relay switched the gate reservoirs from 
ground to -4.5 kV for 1.25 s, allowing short plugs of solution from the reaction channels 
to be loaded onto the separation channels where the Ab bound and free FITC-ins were 
separated by electrophoresis.  A single relay actuated all of the gates simultaneously.  
During normal operation, injections and separations were performed at 6.25 s intervals.  
Analyte zones were detected 1 cm from the injection crosses using a scanning confocal 
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fluorescence microscope described below.  The relative peak heights were used to 
quantify the insulin in the islet reservoirs according to a competitive immunoassay 
calibration curve collected prior to the islet measurements.  For calibration, insulin was 
pumped directly into the islet reservoirs using the perfusion system without islets present.  
For islet measurements, the islets were perfused with BSS containing different 
concentrations of glucose. 
 Multiplexed Laser-induced Fluorescence and Data Analysis.   LIF detection of 
multiple separation channels was accomplished using a laser-scanning confocal 
microscope (RCM 8000, Nikon, Melville, NY) operated in line scan mode.  To facilitate 
detection, the chip was designed so that the detection point 1 cm downstream from the 
injection cross was aligned for all four networks.  The microscope, when operated in line 
scan mode, scans a laser spot from the 488 nm line of a water-cooled Ar+ laser 
(Coherent, Santa Clara, CA) bidirectionally across a sample surface at 15.75 kHz.
23
  In 
order to achieve scanning across the entire detection region of the chip, a 10x (0.3 
numerical aperture (NA)) microscope objective (Nikon, Melville, NY), allowing an 
estimated scanning distance of 470 µm, was used to focus on the detection points.  The 
chip detection region (Figure 2.1C) was designed to fit within this scan distance.  With 
this field of view, eight channels (23 µm wide at the top with 35-µm edge-to-edge gaps 
between each) could be probed with each scan.  Four of the channels running across the 
detection line are separation channels while the others are waste channels (a consequence 
from using the flow gate injection design).  The passing of the waste channels (through 
which fluorescent solution was continuously flowing) across the detection zone 
35 
 
facilitated alignment of the device in the z-axis.  Alignment marks on the chip allowed 
reproducible placement of the detection zones for each channel on the laser scan line. 
Line scan data were collected and recorded on optical disk cartridges (TQ-FH332, 
Panasonic, Secaucus, NJ) using an optical disk recorder (TQ-3038F, Panasonic).  Each 
frame of data on an optical disk (containing 525 line scans) was averaged to a single data 
point to produce an overall 30 Hz sampling rate.  Electropherograms were constructed by 
plotting the fluorescence intensity from fixed points within the line scans using 
MetaMorph software (Universal Imaging, Downingtown, PA).  The resulting parallel 
electropherograms were subjected to a seven-point moving average smooth before being 
analyzed using software written in-house.
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Islet Isolation Protocol.   Pancreatic islets were isolated from 20 to 30 g male 
CD-1 mice using a previously described method.
108
  Briefly, mice were sacrificed by 
cervical dislocation before collagenase type XI was injected into the pancreas via the 
main pancreatic duct.  The pancreas was removed and exposed to a collagenase solution 
at 37 °C.  A Ficoll gradient was then used to separate islets from exocrine tissue.  Islets 
that were selected for experiments had a diameter of 100 to 200 µm, an intact islet 
membrane, and an oblong to spherical shape.  The islets were incubated in RPMI 1640 
cell culture media with 10% fetal bovine serum, 100 units mL
-1
 penicillin, and 100 µg 
mL
-1
 streptomycin at 37 °C and 5% CO2.  Islets were used 1-6 days after isolation. 
 
Results and Discussion 
 Continuous Parallel Measurements.   Typical electropherograms obtained in 
parallel with online mixing of the Ab and FITC-ins reagents are shown in Figure 2.2, 
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illustrating the completion of 20 immunoassays in 30 s.  Each separation consists of a 
FITC-ins:Ab complex zone that is detected before a free FITC-ins zone.  Migration time 
relative standard deviations (RSDs) for the single channel networks are less than 1% for 
five consecutive injections and slightly larger (2%) for migration times over all four 
channels.  RSDs of this magnitude were typical for all experiments performed with this 
chip design.  These low values suggest good reproducibility of glass surface properties 
and resulting EOF between separation channels.  This reproducibility also suggests that 
the electric fields across each of the four channel networks are of similar magnitude, 
indicating little or no current leakage between channels.  It is possible that the migration 
times could have been affected by both the alignment and wobble associated with the 
laser scan line, but judging from the achieved precision, these aspects of the instrumental 
setup seem to have little effect.  Good reproducibility is important because a single relay 
is used to control the injections.  If migration times drifted, or were significantly 







Figure 2.2. Typical series of parallel electropherograms obtained from online mixing of reagents.  
Solutions of 250 nM FITC-ins, 250 nM Ab, and 100 nM insulin standard were continuously mixed 
online while CE-LIF analyses were made every 6.25 s.  Bound (B) and free (F) peaks are indicated by 
arrows.  Fluorescence signal is in arbitrary units (AU) and offset for clarity. 
 
The separation potential used for the separations in Figure 2.2 was -5 kV.  As the 
separation channel is electrically coupled to the reaction channel, it was necessary to 
determine an appropriate potential that allowed for fast separations but still gave an 
adequate reaction time for the competitive immunoassay.  It was observed that the 
application of -5 kV to the waste reservoirs, yielding a separation field of 600 V cm
-1
, 
allowed for the separation of the bound and free zones in less than 5 s while giving a 60 s 
reaction time for the immunoassay.  This reaction time was deemed adequate for these 
experiments given that it was found to produce easily detectable B/F values.
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Rapid serial injections after online reaction, necessary for continuous monitoring 
of insulin release from islets, was made possible through the use of a microfluidic flow 





injection designs, facilitates the continuous monitoring of a sample with online reactions 
because the field strength in the separation channel remains similar during injection and 
separation, allowing for continuous flow through the reaction channel during both modes.  
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In contrast to previous designs of parallel immunoassay chips that required the stopping 
or reversal of flow during a separation,
26
 this design can perform serial immunoassays 
that allow continuous monitoring of the sample chamber.  However, one disadvantage 
with this design is that waste channels must pass through the detection area, limiting the 
space available for additional separation channels.  It is also possible to obtain continuous 
monitoring by using a modification of the pinched injection mode.  This design may 
allow more channels in the detection zone and would have the added advantage of less 
electrophoretic discrimination in the injection.
112
 
 Calibration.   Calibration of the device was performed by perfusing standard 
insulin solutions into the islet reservoir of the chip with no islets present.  Figure 2.3 
represents a typical calibration curve for a microchip, obtained using standards between 1 
and 500 nM insulin.  (All standards were dissolved in BSS to replicate conditions used 
for living islet experiments.)  The calibration curves for each channel network all show a 
similar dose-response function that is characteristic of antigen-antibody binding; 
however, some variation is seen from network to network.  Previous studies using 
parallel CE-based immunoassay chips also showed irregularity between data collected 
from multiple manifolds on a single device, which was partially attributed to nonuniform 
surface characteristics across a single glass wafer.
26
  Results from experiments discussed 
in future chapters support this theory.  Regardless of the origin, the fluctuation of 
performance is not a concern as long as calibration of each individual channel network is 






Figure 2.3. Calibration curves obtained with the four-islet chip.  The curves were obtained while 
perfusing insulin standards (1 – 500 nM) into the islet reservoirs with no islet present.  Data points 
are averages of five consecutive electropherograms.  Error bars are ± 1 standard deviation. 
 
Data points in Figure 2.3 are the average of five electropherograms collected in 
series.  The average RSDs for data points from each single network range between 8 and 
9% (corresponding to 6 – 100 nM insulin depending on location in standard curve).  
LODs for the channel networks, calculated as the concentration of analyte required to 
produce a change in B/F that is greater than 3 times the standard deviation of the 
background B/F, were 10 nM insulin for networks 1, 3, and 4 and 7 nM insulin for 
network 2.  These LODs are roughly 10-fold worse than those reported with the previous 
single islet microchip (0.8 nM insulin). 
The increase in detection limit is ultimately a result of using a scanning detector, 
which lessens the time available for the analysis of a single detection point.  In the 
detector used here, the laser spot is continuously moving across the sample surface, and 
as a result, spends much time focused on regions of the chip that do not generate signal.  
Furthermore, the objective magnification was reduced to 10x and 0.3 NA compared to 
40x and 0.6 NA used for single-islet chip studies.  This change gave a wider field of 
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view, allowing multiple channels to be detected, but it also decreased the light collection.  
Because of these limitations, it was necessary to increase the concentrations of 
immunoassay reagents (Ab and FITC-ins) used for islet experiments from 50 nM each 
(point detection) to 250 nM each in order to maintain a detectable signal.  The higher 
reagent concentrations decreased the sensitivity of the immunoassay.
113
  Although this 
increase in immunoassay reagent concentration ultimately produced a less sensitive 
system, it was still sufficient for the detection of insulin release from single islets.  
Presumably a more sophisticated detector design
30
 would be beneficial in these 
circumstances by allowing longer data acquisition times, increased instrumental 
sensitivity, and lower reagent concentrations. 
In addition to increasing reagent concentration, the injection volume for each 
separation was increased (when compared to the single islet microchip with point 
detection) to help compensate for the decreased detector sensitivity.  Increased injection 
times resulted in poorer resolution of the bound and free peaks than what was previously 
obtained with the single islet chip.
 
 It was found that an injection time of 1.25 s, yielding 
315 pL of injected sample, allowed for adequate responsivity of the detection system 
while retaining sufficient resolution for a peak height ratio analysis. 
Although the use of microfluidics offers the expediency of disposable devices, it 
is convenient to fabricate chips that can be reused throughout a series of experiments.  
Figure 2.4 illustrates channel network calibration drift of a single device over a period of 
two weeks.  During these two weeks, the microchip was conditioned and used daily.  The 
figure shows typical three-point “daily” calibration curves, fitted from the linear portion 
of the full dose-response curves.  All of the plots show little drift in calibration after three 
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days of use.  Some of the networks, however, show significant drift after 14 days of use, 
necessitating recalibration of the device before this time.  The calibration plots used for 
islet studies were performed daily and collected immediately before each experiment. 
 
Figure 2.4. Calibrations obtained on each channel network over a two week period of continuous use.  
Standard insulin solution concentrations used were 10, 100, and 200 nM.  Data points are the average 
of five consecutive electropherograms.  Error bars are ± 1 standard deviation. 
 
 
Characterization of Insulin Secretion from Multiple Pancreatic Islets.   The 
ability of the microchip to continuously monitor the extracellular environment from 
multiple independent living biological entities was tested by detecting glucose-stimulated 
insulin secretion from islets of Langerhans.  These experiments were performed by 
placing a single islet in each of the islet reservoir access holes and serially analyzing 
perfusate for insulin as the glucose concentration was altered in the perfusion fluid.  
Panels A-D in Figure 2.5 show insulin secretion from four islets monitored 
simultaneously on a single chip.  All the islets show an increase in insulin secretion with 
the perfusion of 11 mM glucose and a decrease to basal levels with return to 3 mM 
glucose as expected.  Despite the similarities in overall levels and response, the temporal 
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patterns show variability that illustrates the classical patterns of insulin release from 
individual islets.  The secretion pattern in Figure 2.5A shows an initial burst or “first 
phase” of insulin secretion at ~3 min after the perfusion of 11 mM glucose BSS.  It is 
also known that some islets will give rise to oscillatory secretion, as illustrated by the 
data in Figure 2.5B-D.
87,114,115
  The period of oscillations observed here is in good 
agreement with previous observations of 2 and 3 min periods for isolated islets.  The 
variability of single islet data is common and illustrates the need to collect data from 
multiple individuals to gain insight into the overall response. 
 
Figure 2.5. Insulin release from islets of Langerhans measured on a multiplexed microfluidic chip.  
Error bars (± standard error of the mean) are placed every five data points for clarity.  Bars placed 
above plots indicate step changes of glucose concentration in perfusion buffer (low bar 3 mM glucose, 
high bar 11 mM glucose).  Scales on right side of panels A – D indicate concentration of insulin (nM).  
Detected insulin secretion from four islets (A – D) on a single chip is shown.  Averaged insulin 





Figure 2.5E represents the averaged insulin secretion data from Figure 2.5A-D, 
and Figure 2.5F shows the average of another set of four islets.  A comparison of the data 
from (E) and (F) reveals the similarity of averaged responses from different experiments.  
Despite individual variations, the plots show that the averaged basal secretion, peak 
secretion, time to peak, and sustained level after peak are all similar to each other, 
illustrating the reproducibility of the method and averaged islet behavior. 
For all eight islets tested, the average rate of insulin release was 27.0 (1.6 pg min
-1
 
per islet under basal conditions (perfusion of 3 mM glucose BSS)).  Secretion increased 
by an average of 350% to just under 100 pg min
-1
 per islet after stimulation with 11 mM 
glucose BSS.  The percent increase and absolute level are in good agreement with other 
studies performed under similar conditions that used either single islets or groups of islets 
and monitored release using ELISA or RIA.  Recently, a study monitoring insulin release 
rates from mouse islets showed secretion at or below ~100 pg min
-1
 per islet resulting 
from a step change from perfused 3 to 15 mM glucose.
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Advantages of Parallel Islet Analysis.   These results illustrate that the 
microchip can be used to simultaneously quantify chemical secretions from four islets, 
giving a four-fold increase in throughput over the single islet chip.  The ability to operate 
individual biological experiments in parallel, even those requiring complicated 
measurements such as serial immunoassays, offers important savings in time and cost.  In 
islet experiments, as in any biological experiment, it is necessary to perform numerous 
replications to determine the statistical significance of differences due to experimental 
manipulations.  Such replications can be time-consuming when studies are performed at 
the single-entity level.  For example, the throughput of single islet secretion experiments 
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is typically just 1-3 islets per day.  Therefore, although 70 islets can typically be isolated 
from a single mouse, only a fraction can be used for experiments because islets are stable 
in culture for just few days.  As a result, multiple mice must be sacrificed and numerous 
islet isolations performed to obtain enough samples for replicate experiments.  Given the 
high costs of labor and animal models, especially genetic knockout mice, low throughput 
becomes expensive.  Another significant cost savings is in the assay itself.  The data in 
panels E and F in Figure 2.5 represent over 1450 immunoassays.  Performing a similar 
number of assays using conventional immunoassay technology (which would be difficult 
because of the sensitivity required) would cost ~$8200, just for reagents at typical prices 
of ELISA kits.  In contrast, the reagents used for these assays cost under $60. 
 An increase in the number of networks in parallel would be desirable in order to 
further capitalize on cost and time savings.  As use of this line scan detector limits the 
size of the detection window to a slit that is ~470 µm long (when using a 10x objective), 
it may be possible to increase channel density through the detection window by 
decreasing the spacing between channels.  This approach could possibly double the 
number of channels detected, provided the resulting interchannel space is thick enough to 
maintain electrical isolation.  While this design change would allow higher sample 
capacity, it is likely this would also result in a lower duty cycle and ultimately higher 
detection limits. 
In the present design, only half of the channels that pass through the detection 
window are separation channels.  A change in the microfluidic configuration, such as a 
modified pinch injector, may allow all of the channels passing through the detection 
window to be separation channels and thus double the number of islets simultaneously 
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monitored without any loss of sensitivity.  The use of scanning detectors that allows 
larger areas or different shapes to be observed, such as a laser-excited rotary confocal 
scanner, would allow a further increase in number of channels that can be monitored.  
Scanning over ever larger areas, however, may ultimately be limited by decreases in 
signal-to-noise ratio because of the reduced duty cycle.  This problem is especially acute 
for the rapid separations used in this application because they require fast scan rates for 
adequate data sampling.  The use of imaging detectors as opposed to scanning detectors 
may be useful for fast separations because they would allow continuous observation of all 
points in the detector window, thus lessening geometric constraint and allowing more 
channels to be detected simultaneously. 
 
Conclusions 
 A microfluidic device capable of performing serial immunoassays in parallel for 
chemical monitoring of the environment around living cells was developed.  The 4-fold 
higher throughput results in substantial time and cost savings over a single-sample device 
for physiological experiments.  Although the LOD is ~10-fold higher than the single-
channel device, it was still sufficient for monitoring insulin secretion at 6.25 s intervals 
from single islets.  Future directions will involve an increase in throughput and improved 
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Insulin secreted from pancreatic islets helps to maintain glucose homeostasis 
through actions at the insulin receptor in target tissues including liver, muscle, and 
brain.
117
 Impaired insulin secretion is a hallmark of diabetes which is a prevalent and 
growing health problem.  Type 1 diabetes is characterized by autoimmune destruction of 
β-cells.  Islet transplant
118
 and development of insulin-secreting cells derived from stem 
cells
84
 are receiving active research interest as possible treatments for this disease.  Type 
2 diabetes is characterized by insulin resistance (i.e., poor response to insulin by target 
tissues) and insufficient insulin release from β-cells to overcome this resistance.
104
 
Research into the causes and treatments of diabetes routinely requires measurement of 
insulin secretion.  The long analysis time of traditional secretion measurement methods 
utilizing ELISA or RIA hampers the use for certain clinical applications such as 
evaluating the quality of islets prior to transplant.  Additionally, these types of 
experiments are of interest for studying the kinetics of insulin secretion, and so methods 
for measuring insulin release from single islets with fast temporal resolution are of 
significant biomedical interest. 
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Microdevices developed in our lab have greatly simplified measuring insulin 
secretion from single islets at high temporal resolution.  In these devices, insulin release 
from single islets is detected at 5 to 10 s intervals with an electrophoretic 
immunoassay.
92,93
  While useful, these devices suffer from a practical problem in that 
they have a low throughput for islet experiments.  To increase throughput, a four-islet 
system was developed.
49
  While an improvement, the detection system had relatively 
poor sensitivity and the improved throughput was not sufficient to justify the compromise 
in performance.  The goal for the work presented here was to develop an easy-to-use 
parallel system that would further increase throughput for islet experiments without 
compromise on immunoassay sensitivity. 
A key design consideration for microfluidic devices with parallel separation 
systems is the arrangement of the detection zones as this has a large impact on the 
number of separation channels that can be incorporated as well as the complexity of the 
detector.  In our previous on-line parallel immunoassay system,
49
 and with most other 
parallel systems on chips, the detection zones are arranged along a line with separation 
channels running parallel to each other.  Such an arrangement allows relatively simple 
optics, either an excitation source shaped to a line or linear scanning of a laser (readily 
available on commercial microscopes), to be used for fluorescence detection. 
It has been demonstrated that substantial improvements in parallel operation can 
be achieved by using a radial channel design.
30
  In this design, sample preparation and 
injection zones are arranged in a circle on the outside rim of the chip while the separation 
zones converge towards a common outlet at the center.  This design uses the space on a 
chip more efficiently because the detection zones are confined to a small space at the 
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center of the device while the multiple reservoirs and inlets required for sample 
manipulation are placed along the outer rim of the chip with more area.  Radial designs 
have allowed multiplexing of 96 and 384 electrophoresis channel arrays.
30,31
  Sensitive 
fluorescence detection on these devices has been performed using a custom-built rotary 
scanning confocal detector.  While this has been shown to be an effective detector, the 
use of charge-coupled device (CCD) cameras for imaging detection on multiplexed 
chips
33,37,46,51
 suggests the potential for high throughput analysis with microfluidic 
devices using a less complicated detector.  
In this work we have adapted a radial design to parallel, online, serial 
immunoassay for cellular monitoring.  To simplify detection, we utilize a commercially 
available fluorescence imaging microscope with an electron-multiplying CCD for 
detection.  We show that this detector, while not as sensitive as the scanning confocal 
design, has adequate sensitivity for the insulin immunoassay as well as sufficient speed 
for monitoring the rapid separations used here.  With this detector and radial design, we 
were able to successfully operate 15 channel networks in parallel and simultaneously 
monitor insulin secretion from 15 islets. 
 
Experimental Section 
 Chemicals and Reagents.   Balanced salt solution (BSS) used as a physiological 
buffer for islets experiments consisted of 125 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 
2.4 mM CaCl2, 25 mM tricine, and 0.7 mg mL
-1
 bovine serum albumin (BSA), adjusted 
to pH 7.4 with NaOH.  Buffer for immunoassay reagents was 50 mM NaCl, 1 mM 





 BSA, adjusted to pH 7.4.  Separation buffer consisted of 20 mM NaCl and 150 
mM tricine, adjusted to pH 7.4. 
 Tricine, electrophoresis grade, was purchased from MP Biomedicals (Aurora, 
OH).  Collagenase type XI, insulin, EDTA, fluorescein, and Tween 20 were from Sigma 
(St. Louis, MO).  Cell culture reagents were from Invitrogen (Carlsbad, CA).  Fluorescein 
isothiocyanate-labeled insulin (FITC-ins) was obtained from Molecular Probes (Eugene, 
OR), and monoclonal antibody (Ab) to human insulin was from Biodesign International 
(Saco, ME).  All other reagents were from Fisher (Pittsburgh, PA).  All solutions were 
made with 18-MΩ deionized water from a Millipore (Bedford, MA) Milli-Q filtration 
system and filtered with 0.2 μm nylon syringe filters (Fisher). 
Stock FITC-ins was diluted to 166 μM using the immunoassay reagent buffer 
(without Tween 20) and stored at -32 °C until use.  Stock Ab solution was stored at 4 °C 
following the manufacturer’s instructions. 
 Microfluidic Chip Fabrication.   The microfluidic device illustrated in Figure 
3.1A was fabricated from borofloat glass using previously described wet-chemical 
etching techniques.
49
  Channels were etched to 15 μm deep with a hydrofluoric acid 
etching solution.  Access holes to the microchannels were drilled with 360 μm diameter 
drill bits (Tartan Tool Co., Troy, MI).  The four perfusion inlet connectors were from 
Upchurch Scientific (Oak Harbor, WA).  The remaining fluidic reservoirs were made in-
house from polytetrafluoroethylene (PTFE) tubing obtained from McMaster-Carr 
(Aurora, OH) and attached to the chip with epoxy (E-6000, Eclectic Products, Inc., 




Figure 3.1. Channel layout of a radially designed microfluidic chip for monitoring insulin secretion 
from 15 independent islets.  (A) The channel network of the entire device.  Microfluidic channels are 
indicated by solid black lines, and circles represent fluidic reservoirs.  Each type of fluidic reservoir 
(holding a different solution) is color-coded for clarity.  Operation of the chip is described in the 
Experimental Section.  (B) Brightfield image of the detection area taken with the CCD camera. 
 
Microfluidic Chip Preparation and Operation.   The microfluidic chip design 
in Figure 3.1A consists of 15 channel networks, each capable of continuously monitoring 
insulin levels using an online competitive immunoassay coupled to capillary 
electrophoresis (CE) separation with fluorescence detection.  Flow through the separation 
channels converges at a common point for fluorescence detection and then continues into 
a single waste channel. 
Electrical connections to 48 of the fluidic reservoirs were made with a chip-
electrode interface built in-house.  Two separate high voltage power supplies 
(CZE1000R, Spellman High Voltage Electronics, Hauppauge, NY) were used to apply 
potential to the waste reservoirs (-HV1 and -HV2) and a single high-voltage relay 
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(Kilovac, Santa Barbara, CA), controlled by a LabVIEW program, connected the gate 
reservoirs to ground. 
Prior to daily use, channels were rinsed with deionized water by applying vacuum 
to the common waste (-HV2) reservoir for ~5 min.  Chips were then conditioned in a 
similar fashion with 0.1 M NaOH.  After conditioning with pressure-driven flow, 
electroosmotic pumping of NaOH solution was used to condition channels individually 
by applying a negative high voltage to the common waste (-HV2) reservoir and grounding 
the other reservoirs one or two at a time.  Using electroosmotic pumping to condition all 
channel networks simultaneously was not feasible as this produced an electrical current 
higher than the maximum rating of the power supplies used.  Electroosmotic pumping of 
NaOH in every channel yielded uniform conditioning of the parallel networks and was 
found to help reduce the variability of flow across the entire chip.  After conditioning 
with NaOH, the chip was flushed again with deionized water and finally with buffer 
solutions. 
For islet experiments, single islets were placed in each islet reservoir access hole 
with BSS and perfused with a glucose solution.  A thin film heating strip (Minco, 
Minneapolis, MN) was attached to the underside of the chip to maintain islet viability 
during the experiment by heating the access holes to 37 °C.  Solutions of 50 nM FITC-ins 
and 40 nM Ab (both in immunoassay reagent buffer) were placed in FITC-ins and Ab 
reservoirs, respectively.  Separation buffer was placed in the remaining fluidic reservoirs. 
Perfusion of the islets with physiological buffer was accomplished by connecting 
the perfusion inlets on the chip to a five-port manifold (Upchurch Scientific) with fused-
silica capillary (250 μm i.d., 360 μm o.d.) and then to a vial of perfusion solution 
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contained in a pressurized stainless steel reservoir.  This setup allowed the perfusion of 
15 independent islets using a single solution.  Application of 125 kPa to the reservoir 
provided a flow of 0.6 μL min
-1
 to each islet.  The pressure-driven flow from the 
perfusion system did not result in any significant hydrodynamic flow within the rest of 
the microchip because the islet perfusion chambers were open to atmosphere, allowing 
the majority of flow to exit into the fluidic reservoirs positioned over the islets. 
Insulin that was secreted from the islet was sampled electrophoretically by 
grounding the islet reservoir and applying -4 kV to the common waste (-HV2) reservoir.  
FITC-ins and Ab reservoirs were also grounded allowing the sampled insulin to mix and 
react with the immunoassay reagents while flowing through the reaction channels.  A 
potential of <-1 kV was applied to the gating waste (-HV1) reservoirs, diverting flow 
from the reaction channels towards the gating waste (-HV1) reservoirs while the gate 
reservoirs were at ground.  A single high-voltage relay was used to switch all the gate 
reservoirs from ground to float (open circuit) which allowed small plugs of the reaction 
mixture to enter the 15 separation channels.  Injections of 0.5 s were performed at 10 s 
intervals.  After the gate reservoirs were returned to ground, flow from the reaction 
channels was again diverted by separation buffer and the sample plugs in the separation 
channels were separated by CE.  Fluorescence detection was performed at the point of 
separation channel convergence, yielding an effective separation distance of 1 cm. 
Separation of the two fluorescent products (bound FITC-ins:Ab and free FITC-
ins) allowed comparison of peak heights to be used to quantify the amount of insulin 
introduced to each channel network.  Calibration of the microchip was performed by 
operating the device while perfusing insulin standards into the chip without the presence 
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of islets.  This allowed specific bound FITC-ins:Ab and free FITC-ins peak height ratios 
to be assigned to insulin concentrations. 
Fluorescence Detection and Data Analysis.   Simultaneous fluorescence 
detection of all separation channels was accomplished by collecting time-lapse intervals 
of fluorescence images using an inverted epi-fluorescence microscope (IX71, Olympus 
America, Inc., Melville, NY).  Fluorescence excitation light was from a 300 W Xe arc 
lamp (LB-LS/30, Sutter Instrument Company, Novato, CA) and passed through a FITC 
filter cube (Semrock, Rochester, NY) before being focused on the chip detection region 
with an objective lens (Olympus America Inc., Melville, NY).  Emitted fluorescence was 
collected with the same objective and detected using an electron-multiplying CCD 
camera (C9100-13, Hamamatsu Photonic Systems, Bridgewater, NJ).  In order to image 
the entire detection region of the chip with the highest light gathering efficiency, a 20x 
objective lens (0.75 numerical aperture) that allowed for the collecting of 400 x 400 μm
2
 
images was selected for fluorescence detection.  A sample brightfield image taken using 
this objective (Figure 3.1B) shows all 15 separation channels and the common waste 
channel within the detection region. 
Images were collected at ~28 Hz (to allow for adequate sampling of 
electrophoresis separations), stored, and analyzed with SlideBook software (Intelligent 
Imaging Innovations, Inc., Denver, CO).  Fluorescence intensities from 35 μm diameter 
regions of interest that corresponded to each separation channel were extracted to 






Isolation of Murine Islets.   Pancreatic islets were isolated from 20 to 30 g male 
CD-1 mice as previously described.
108
  After isolation, islets were incubated at 37 °C and 
5% CO2 in RPMI cell culture media supplemented with 10% fetal bovine serum, 100 
units mL
-1
 penicillin, and 100 μg mL
-1
 streptomycin.  Islets were used 1 – 6 days after 
isolation.  Islets chosen for experiments were of average size (100 – 200 μm diameter) 
and with an intact membrane. 
 
Results and Discussion 
 Multiplexed Detection with an Electron-Multiplying CCD Camera.   By 
arranging 15 separation channels in a radial fashion, with all flow leading to a common 
point before exiting through a common waste channel (Figure 3.1), fluorescence 
detection of all networks could be accomplished using standard fluorescence microscopy 
with an imaging detector.  The detection limit of the system was tested by injecting 8 nM 
fluorescein for 0.5 s (yielding the introduction of 250 pL of sample) at 10 s intervals 
while imaging at 28 frames per second.  As shown by the electropherograms in Figure 
3.2, a reasonable signal to noise ratio was obtained and the limit of detection (LOD) was 
~600 pM.  LODs as low as 10 pM fluorescein have been reported from the use of 
scanning laser detection systems with parallel chip designs;
30
 however, this value was 
obtained by continuously flowing fluorescein through separation channels.  When a 
similar experiment was performed with the microdevice and detector used in this study, 
an LOD of 160 pM was obtained. In contrast, previous reports of groups using 







Figure 3.2. Electropherograms obtained by making serial injections of 8 nM fluorescein.  Injections 
and separations were performed in parallel on the device; however, only data from a single network 
are shown.  Data are shown in relative fluorescence units (RFU). 
 
 
The dynamic range (i.e., concentration window that will yield a change in bound-
to-free ratio, B/F) and LOD of a competitive immunoassay are determined in part by the 
concentration of antibody and labeled antigen used in the assay.
113
  For immunoassay 
dynamic range and LOD comparable to what was previously obtained with the single 
sample device,
93
 it was necessary to use 50 nM FITC-ins (higher concentrations can be 
useful but give worse sensitivity).  Therefore, even though the LOD for fluorescein 
obtained using the CCD camera on this chip is worse than that achieved with custom-
built laser scanning detectors, it is sufficient for achieving detection limits in the 
immunoassay that are comparable to our previous work.  The simplicity and commercial 
availability of the CCD system for detection make it an attractive alternative for this 
application.   
 Microfluidic Chip Design and Performance.   After determining that the LOD 
for the system was adequate, device operation was tested by the collection of serial 
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immunoassays with online reagent mixing on this system.  Typical serial 
electropherograms collected after mixing FITC-ins, Ab, and insulin online in each 
channel network are illustrated in Figure 3.3A and B.  Each panel shows five separations 
consisting of a peak for the FITC-ins:Ab complex (bound) and the slower migrating 
FITC-ins (free).  The separations shown in the figure were performed on the same 
channel but with 1 and 100 nM insulin in the sample respectively.  The change in peak 
heights observed in panels 3.1A and 3.1B was caused by the addition of insulin which 
shifted the ratio of bound and free FITC-ins through a competitive binding reaction.  
Relative standard deviation (RSD) for migration times on a single microfluidic 
network/separation channel are less than 1% (n = 5 separations).  RSDs for single 
channel B/F were less than 3.5% for n = 5 separations with 100 nM insulin.  Over 20 min 
of continuous operation (120 assays) the RSD was slightly larger at ~6%, correlating to 




Figure 3.3. Typical serial and parallel electropherograms obtained with online mixing of 
immunoassay reagents.  Injections were made every 10 s.  FITC-ins bound complex [B] and free 
FITC-ins [F] are labeled accordingly.  (A) Serial electropherograms collected when mixing 50 nM 
FITC-ins, 40 nM Ab, and 1 nM insulin standard.  (B) Electropherograms collected after the 
introduction of 100 nM insulin standard into the same channel used in (A).  RFU values are shown in 
(A) and (B) to allow peak height comparisons.  (C) Serial electropherograms collected in parallel 
after introduction of 100 nM insulin standard using all 15 channel networks.  Traces are offset for 
clarity. 
 
Figure 3.3C illustrates serial electropherograms collected in parallel using all 15 
networks on the device.  Migration time RSD across the entire chip is less than 6%.  
Although this is an increase from the previous four-sample chip (migration time RSD = 
2%), it is acceptable as a variation of this magnitude does not significantly slow the rate 
at which immunoassays can be completed.  Good reproducibility between networks is 
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important for separations in parallel using a single relay for injections because serial 
analyses can only be performed as fast as separations occur on the slowest channel.  The 
averaged B/F RSD across all 15 channels was 11.7%. 
Application of -4 kV to the common waste (-HV2) reservoir yielded electrical 
current that was close to the maximum rating of the power supply.  Thus, the power 
available limited the electric field to ~400 V cm
-1
, which was 1/3 lower than previous 
chips, producing slower separations and reducing temporal resolution from 6 s to 10 s.  
Although lower, 10 s injection frequency is still adequate for the characterization of 
single islet insulin secretion dynamics.  It is feasible that a power supply with a higher 
power rating can be used for faster separations.  It is also possible to reduce the channel 
depth to yield lower current and faster separations, but we found that this decreased 
detection sensitivity; therefore a channel depth of 15 µm was used as the best 
compromise with this power supply and detector. 
Calibration.   The device was calibrated by perfusing insulin standards (dissolved 
in BSS) into the islet reservoir while monitoring B/F by online immunoassay.  Typical 
calibration curves for all 15 networks collected simultaneously are shown in Figure 3.4.  
While the curves vary slightly in shape and slope, all have the expected dose-response 
shape characteristic of competitive immunoassays.
113
 The reason for variation in dose 
response curves among the different channels is not clear.  Reports of other parallel 
microfluidic chips have discussed non-uniform flow characteristics across a single 
device,
26,30,48
 and it is possible that the variations observed in curve shape are due to 
slightly different FITC-ins and Ab mixing ratios resulting from non uniform channel 
surfaces properties.  To ensure that the variation between calibration curves did not affect 
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the calculated insulin levels in any particular network, each network was calibrated 
before an islet experiment.   
 
Figure 3.4. Calibration curves for all 15 networks obtained with insulin standards (0.1 nM – 500 nM) 
and the online immunoassay.  Numbers in upper right corner of each plot indicates channel network 
number.  Error bars are ±1 standard deviation.  Data points are averages of five consecutive 
electropherograms. 
 
Although the curves are variable enough to require individual calibration of each 
channel, the dynamic range in each curve was consistently useful for single islet 
experiments.  Calibration curves ranging from 5 to 200 nM insulin (corresponding to B/F 
ratios typically observed from an islet) were collected each day before an experiment.  
The LODs (calculated as the concentration of analyte required to produce a change in B/F 
that is greater than 3 times the standard deviation of the background B/F) from the 
calibration curves in Figure 3.4 were between 0.5 and 1 nM insulin.   
Comparison to Four-sample Parallel Microchip.   The 15-sample microchip 





The increase in throughput is a result of both the inclusion of a radial design of channel 
networks and the modification of the microfluidic flow-gate injector that was used on the 
four-sample chip.  The type of flow-gate injector used on these chips allows for periodic 
sampling from the continuously flowing reaction mixtures.  The previously used injector 
type was designed to minimize the number of power supplies needed for analysis;
119
 
however, this necessitated waste channels running parallel to separation channels to also 
pass through the detection area, ultimately decreasing the number of parallel analyses that 
can be performed.  In contrast, the design used here has flow-gate injectors with 
decoupled waste channels controlled by a second power supply, eliminating the need for 
waste channels to run parallel to separation channels and allowing for increased 
separation channel density within the detection area.  
In addition to the increase in throughput, LOD was improved 10-fold in 
comparison to the four-sample chip that used a commercial scanning confocal detector.  
This improvement in LOD can be attributed to the increased sensitivity of the detection 
scheme which has allowed for a decrease in immunoassay reagent concentrations 
(currently 50 nM FITC-ins and 40 nM Ab, previously 250 nM FITC-ins and 250 nM Ab).  
This improved LOD is significant as it allows for quantification of lower amounts of 
insulin that are secreted from an islet in low glucose conditions.  The previous four-
sample chip had an LOD of 10 nM insulin which corresponds to 35 pg min
-1
 at 0.6 µL 
min
-1
 islet perfusion.  Because observed average secretion rates from islets perfused at 3 
mM glucose are close to this value, this detection limit was barely sufficient to detect this 
lower level of release.  The 15-sample chip has an LOD of less than 7 pg min
-1
 using the 
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same perfusion conditions meaning that basal secretion can be routinely detected and 
quantified with this device.  
Parallel Measurement of Insulin Release from Pancreatic Islets.   
Functionality of the 15-sample microchip was tested by simultaneously monitoring 
insulin secretion from 15 individual islets stimulated with glucose.  Figure 3.5A 
represents 15 insulin secretion profiles from independent islets stimulated with a 3 mM to 
11 mM glucose step change.  A variety of secretion dynamics that are typical of isolated 
islets are seen among the 15 profiles including pronounced 1
st
 phase “bursts” and 
oscillatory secretions.
87,120
  An averaged plot of all 15 profiles (illustrated in Figure 3.5B) 
shows a biphasic insulin secretion profile that is characteristic of pancreatic endocrine 
tissue stimulated with elevated glucose.
103,121
  These results demonstrate the usefulness of 
a high throughput single islet monitoring system by showing the capability of obtaining 
information on the single entity level as well as data that can be made into averaged plots 
(commonly used for islet comparisons between islet types).  Single islet data is important 
because it gives information pertaining to the dynamics of insulin secretion, which can be 






Figure 3.5. (A) Plots showing insulin release rates from single islets collected in parallel using the 15-
sample device.  Perfusion glucose concentration is indicated by bars placed above plots (low bar = 3 
mM, high bar = 11 mM).  (B) Plot showing average insulin secretion rate from the 15 islets in (A).  
Error bars are ± standard error of the mean and placed every other data point for clarity.  (C) 
Comparison of average basal secretion rates (3 mM glucose) and maximum insulin release rates after 
11 mM glucose stimulation of all 15 islets.  Average bars (error bars ±1 standard deviation) show 
good reproducibility between basal and stimulated insulin secretion rates. 
 
 
The results obtained from the 15-sample system agree well with previous 
observations.  The measured basal rates of insulin secretion (34 pg min
-1
 at 3 mM 
glucose) are similar to what has been previously observed in our lab (27 pg min
-1
 with the 
four-sample design and 47 pg min
-1
 with the single sample chip).  This value is also 





) using islet perfusion techniques.
123
  As shown by Figure 3.5B and C, the basal and 
peak rate of secretion across individual islets is similar in magnitude.  These results 
suggest good reproducibility of the perfusion method as well as the sampling of insulin 
across all 15 networks on the device. 
Of the 15 islets reported here, approximately 40% showed oscillations over the 17 
min period of elevated glucose.  Oscillations observed in the single islet plots range in 
duration from 3 to 5 min, agreeing with what has been noted in previous studies that have 
monitored insulin secretion and Ca
2+





 in isolated mouse islets.
114,125,126
 
The averaged insulin secretion plot in Figure 3.5B required 2200 immunoassays 
collected continuously at a rate of 90 per minute.  This high throughput made the 
experiments shown here possible and illustrates the potential of microfluidic devices for 
automating complex cellular measurements.  This system also has a significant cost 
savings as the cost of reagents used was ~$0.01 per assay, less than the approximate 
$0.04 per assay using the four-sample chip and $0.15 per assay with the single sample 
device for experiments of the same length.  Clearly, these devices illustrate a vast 
improvement over typical insulin immunoassay kits that may cost over $5 per assay. 
 
Conclusions 
 We have developed a high throughput microchip for monitoring cellular 
secretions from 15 independent biological samples using a radial alignment of separation 
channels that is compatible for detection using an epi-fluorescence microscope and CCD 
camera.  Testing of the device was accomplished by continuously monitoring insulin 
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secretion from 15 individual pancreatic islets in parallel at 10 s intervals.  While the 
sensitivity of this camera based method is not as good as what has been reported with 
specially built scanning laser-induced fluorescence detectors, it has been shown to be 
adequate for monitoring insulin secretion from islets and shows promise for use in other 
types of assays.  
Further scale up of the number of parallel systems is feasible.  Important factors 
affecting the number of channel networks that can be placed on a device with a radial 
design include network complexity, detection area size, and imaging resolution.  
Complex networks that allow for integrated functioning (such as precolumn reactors and 
multiple perfusion lines in this chip with their associated reservoirs) occupy more area on 
the chip surface than simple CE designs, thus limiting the number of networks that can be 
incorporated.  Detection area can also become limiting because the detection zones for all 
channels must fit within the field of view of the camera.  Using smaller channel widths 
can offset this problem somewhat.  Use of lower magnification objectives can also be 
used to allow for a larger detection region, but this may decrease sensitivity as a result of 
using a lower numerical aperture for collection of fluorescence.  Image resolution is also 
an important consideration in the number of channels that can be incorporated.  In order 
to prevent cross-talk between networks, the collected fluorescence images must be of 






INVESTIGATION OF LEPTIN SIGNALING IN PANCREATIC ISLETS USING 
HIGH THROUGHPUT SINGLE ISLET SECRETION MEASURMENTS 




 The hormone leptin, secreted from adipose tissue, is known to regulate stored 
energy in the body through interactions at the hypothalamus controlling appetite and 
energy expenditure.
127-129
  While these actions have been well characterized, the ability of 
leptin to lower high circulating levels of insulin in ob/ob mice (lacking the ability to 
produce leptin)
130
 and the discovery of leptin receptors on pancreatic cells
131,132
 has 
suggested a direct effect of leptin on endocrine pancreas function.   Indeed, several 
studies have reported leptin having an inhibitory effect on insulin secretion from isolated 
pancreatic islets and β-cells,
133-135
 supporting the presence of a proposed insulin/leptin 
feedback loop.
135
  Levels of leptin in the body are proportional to fat mass, and according 
to the proposed feedback loop, an increase in adiposity and thus leptin would reduce 
insulin production and direct less energy to the formation of adipose tissue.  This 
mechanism is hypothesized to assist in maintaining nutrient balance, and disruption 
would contribute to obesity and hyperinsulinemia associated with diabetes.  However, it 
must be stated that some studies have shown leptin to either enhance
136
 or not affect
137
 




Research in this field has lead to a number of proposed leptin action mechanisms 
on β-cells, summarized in Figure 4.1.  It is thought that leptin signaling in islets directly 
affects insulin production and secretion.  Investigating leptin signaling often utilizes 
mutated mice that lack functional leptin receptors throughout the body (db/db).  
However, as these mice have receptor defects in various tissues, it is difficult to correlate 
observed results with specific effects of leptin on the pancreas.  In an effort to probe the 
direct effects of leptin on the endocrine pancreas, the Kulkarni Lab has developed a 





Figure 4.1. Proposed effects of leptin signaling on the pancreatic β-cell.  The binding of leptin to cell 
receptors may activate the janus kinase/signal transducer pathway (JAK/STAT), eventually leading 
to inhibition of preproinsulin gene transcription.  Several other leptin action possibilities, for 
example involving phosphoinositide 3-kinase and cyclic AMP, are hypothesized that ultimately lead 
to the inhibition of insulin secretion through various pathways.   Reproduced from reference 135.  
 
In a collaborative study, the 15-sample microchip for parallel monitoring of 
insulin secretion (described in Chapter 3) was used to perform in vitro analyses on islets 
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from pancreas-specific leptin ObR knockout mice (KO) and control (ObRlox) animals.  
In addition to probing potential leptin action pathways in islets by monitoring insulin 
release from islets stimulated under various conditions, these experiments served as an 
evaluation of the device for real islet studies involving a variety of experimental 
protocols.  Presentation of in vitro secretion data is accompanied by comparisons to 
results from in vivo experiments (e.g. live animal insulin secretion assays and glucose 
tolerance tests) performed by collaborating research groups for investigations into 
potential mechanisms involving in leptin signaling. 
 
Experimental Section 
Chemicals and Reagents.   Unless otherwise noted, all reagents were from Fisher 
(Pittsburgh, PA).  Cell culture reagents were from Invitrogen (Carlsbad, CA).  Tricine, 
electrophoresis grade, was purchased from MP Biomedicals (Aurora, OH).  Collagenase 
type XI, insulin, ethylenediaminetetraacetic acid (EDTA), Tween 20, mouse recombinant 
leptin,  glibenclamide, fatty acid-free bovine serum albumen (BSA), and palmitic acid 
were from Sigma (St. Louis, MO).    Fluorescein isothiocyanate-labeled insulin (FITC-
ins) and Fura-2 calcium dye were obtained from Molecular Probes (Eugene, OR), and 
monoclonal antibody (Ab) to human insulin was from Biodesign International (Saco, 
ME).  Glucagon-like peptide-1 (7-36) amide (GLP-1) was from Bachem (Torrance, CA).  
All solutions were made with 18-MΩ deionized water from a Millipore (Bedford, MA) 
Milli-Q filtration system and filtered with 0.2 μm nylon syringe filters. 
Buffer Preparation.   Balanced salt solution (BSS) consisted of 125 mM NaCl, 
5.9 mM KCl, 1.2 mM MgCl2, 2.4 mM CaCl2, and 25 mM tricine.  Krebs ringer buffer 
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(KRB) was 118 mM NaCl, 5.4 mM KCl, 2.4 mM CaCl2, 1.2 mM MgSO4, 1.2 mM 
KH2PO4, and 20 mM HEPES.  Buffer for immunoassay reagents was 50 mM NaCl, 1 
mM EDTA, 20 mM tricine, 0.1% (w/v) Tween 20, and 0.7 mg mL
-1
 BSA.  Separation 
buffer consisted of 20 mM NaCl and 150 mM tricine.  All buffers were adjusted to pH 
7.4 with NaOH. 
 Animal and Islet Preparation.   Experiments were performed using a mouse 
model that was deficient in leptin receptors only in the pancreas.
 
  Mice were developed 
by the Kulkarni Lab using the Cre-loxP technique as previously described.
94,138
   All 
animals were housed in specific pathogen free facilities, had free access to food and 
water, and were maintained on a 12 hr light/dark cycle.  Islets were isolated from the 
animals using previously described methods.
108
  Size-matched islets used in experiments 
had a spherical shape and smooth surface indicative of an intact membrane. 
Parallel Microfluidic Assay for Insulin.   Insulin release from single islets was 
measured in parallel using a 15-sample microfluidic chip.  The design and function of 
this microdevice was based on previous secretion monitoring techniques developed in our 
lab.
49,93
  Briefly, 15 single islets were loaded onto the device and perfused with BSS 
containing various amounts of glucose, leptin, palmitic acid, glibenclamide, or GLP-1.  
Portions of the islet perfusate streams were reacted with 50 nM FITC-ins and 40 nM Ab 
on the chip for a competitive immunoassay for insulin.  Immunoassay products were 
separated and detected every 10 s with parallel capillary electrophoresis and multiplexed 
fluorescence detection.  Parallel electropherograms were produced with Slidebook 






Intracellular Calcium Flux Measurements.   Intracellular calcium levels in 
islets were measured with Fura-2 using methods based on previously described 
techniques.
139,140
  Briefly, islets were loaded with 2 µM Fura-2 dye for 45 min at 37ºC 
prior to experiments.  Islets were washed in KRB, loaded into a microfluidic perfusion 
chamber and perfused with glucose and various drugs of interest.  Once perfused, the dye 
was excited by 340 nM (Ca
2+
 complex) and 380 nM (free dye) light and the emission at 





 Effects of Leptin on Glucose-stimulated Insulin Release.   Isolated islets from 
pancreas-specific leptin receptor knockout (KO) and control (ObRlox) mice were tested 
for insulin release and Ca
2+
 flux (a precursor to insulin release) while stimulated using 
glucose with or without the presence of leptin.  Results, illustrated with averaged plots, 
are shown in Figure 4.2.  KO islets showed significantly higher levels of both Ca
2+
 flux 
and insulin release compared to ObRlox islets (statistical analysis, performed here and 
throughout this chapter by comparing the averaged areas under the curve with an 
unpaired 2-tailed Student’s t test, gave P < 0.05), suggesting that inhibition of leptin 
signaling in islets from lean animals may enhance pathways leading to glucose-
stimulated insulin secretion.  Additionally, control ObRlox islets showed noticeably 
inhibited insulin release when perfused with elevated glucose and 10 nM leptin compared 
to those perfused with only glucose (P < 0.05).  Traces from KO islets with and without 






Figure 4.2. Representative traces of intracellular Ca
2+
 flux (A) and insulin secretion (B) measured in 
primary size-matched islets isolated from 6-month-old male ObRlox and KO mice with or without 
100 (A) or 10 nM leptin (B).  Error bars, placed every other point for clarity, are ± standard error of 
the mean (SEM).  Each data set is n = 6 islets.  Reproduced from reference 94. 
 
 
Acute and Chronic Exposure to Fatty Acid.   Acute free fatty acid (FFA) 
exposure experiments were performed by assaying insulin release while perfusing islets 
with glucose and 0.5 mM palmitic acid (±10 nM leptin).  Results are shown in Figure 4.3.  
In both islet types, acute stimulation with FFA and no leptin yielded increases in insulin 
release, though only significant (P < 0.05) in 15 mM glucose regions.  However, 
perfusion of ObRlox islets with 10 nM leptin resulted in no significant (P > 0.05) 
decrease in insulin release compared to traces collected with no leptin either in the 
presence or absence of FFA.  It is thought that the previously observed inhibitory effect 
of leptin (Figure 4.2) may have been masked by the presence of bovine serum albumin 
(BSA) in perfusion buffer (present for appropriate FFA action on cells).  Previous studies 
have also noticed this effect.
133
  A large proportion of plasma leptin (up to 98% in lean 
humans) is thought to be bound to serum proteins,
141
 suggesting that the effects of 




Figure 4.3. Effects of acute FFA exposure on ObRlox (left) and KO (right) islets.  Data sets are from 
islets perfused with glucose solution (± 10 nM leptin) containing 0.5 mM palmitic acid (FFA) or FFA-
free BSA (BSA).   Error bars are ± SEM.  For all sets, n ≥ 5. 
 
 
Chronic exposure of islets to FFA has been shown to inhibit glucose stimulated 





 and gene transcription.
145,146
  As illustrated in Figure 4.4, both islet types 
showed a decrease in insulin release after a 48 hr incubation in RPMI media 
supplemented with 0.5 mM palmitic acid compared to incubation with FFA-free BSA.  
ObRlox islets treated with FFA showed a significant decrease (P < 0.05) in released 
insulin compared to BSA treatment only after perfusion with 15 mM glucose.  KO islets 
with these treatments, however, showed significant decreases in both 8 and 15 mM 
glucose regions of the plot compared to control experiments.  While administration of 
leptin to KO islets showed no effect as expected, ObRlox islets secreted less insulin 





Figure 4.4. Effects of chronic FFA exposure on ObRlox (left) and KO (right) islets.  Data sets are 
from islets incubated for 48 hrs in either 0.5 mM palmitic acid (FFA) or control cell media (BSA), 
and then perfused with 8 and then 15 mM glucose (± 10 nM leptin).  Error bars are ± SEM.  Each 
data set is n ≥ 5 islets. 
 
 
 Stimulation of Islets with Sulfonylurea.   To assess the possible interaction of 
leptin signaling pathways and KATP channel-independent secretion, insulin release was 
measured from control ObRlox and KO islets stimulated with glibenclamide in either 3 
mM or 8 mM glucose with or without the presence of 10 nM leptin.  Results are 
presented in Figure 4.5.  KO islets show significantly higher release (P < 0.05) compared 
to control ObRlox islets in glibenclamide and 8 mM glucose.  Additionally, while no 
effect of leptin on KO islets was observed, it seemed to have a mild, though not 
significant, inhibitory effect on secretion from ObRlox islets in the presence of 8 mM 
glucose.  Ca
2+
 flux measurements using the same protocol (data not shown) showed no 
difference in intracellular Ca
2+
 levels between both types of islets with or without leptin, 
suggesting the differences in observed secretion levels are not due to enhanced Ca
2+
 




Figure 4.5. Insulin release from ObRlox and KO islets stimulated with glibenclamide with or without 
8 mM glucose or 10 nM leptin.  Error bars are ± SEM, all data sets are n ≥ 7. 
 
 
 Effects of GLP-1 and Leptin on Insulin Secretion.  A final series of 
experiments investigated potential leptin interaction with GLP-1 signaling.  ObRlox and 
KO islets were stimulated with glucose and GLP-1 in the presence or absence of leptin.  
Results, illustrated in Figure 4.6, show a number of interesting trends.  For both types of 
islets, the addition of GLP-1 (red traces) yielded significantly (P < 0.05) higher rates of 
insulin secretion compared to islets perfused with glucose only (black traces), agreeing 
with previous studies showing GLP-1 to enhance glucose-stimulated insulin release.
147
  
Additionally, leptin is shown to produce a significant (P < 0.05) inhibitory effect on 
secretion from ObRlox islets both with and without the presence of GLP-1 (red trace vs. 
green trace and black vs. blue in Figure 4.6).  Interestingly, there is no significant 
difference between secretion from ObRlox islets stimulated with glucose, GLP-1, and 
leptin compared to glucose only, suggesting leptin-inhibited insulin release from control 
islets is reversed upon the addition of GLP-1.  These results are consistent with leptin 
signaling interacting with GLP-1 pathways in islets, though, further islet functionality 
studies as well as investigations into expression of known GLP-1 signaling intermediates 




Figure 4.6. Insulin release from ObRlox (left) and KO (right) islets perfused with glucose with or 
without the presence of either 10 nM leptin or 10 nM GLP-1.  Perfusion of leptin and GLP-1 was in 8 




Comparison with in vivo Observations.  Data showing enhanced insulin 
secretion resulting from the removal of leptin receptors from islets (Figure 4.2) 
complements observations from experiments on living animal models.  The effects of 
pancreas-specific ObR removal on in vivo β-cell secretory function were investigated by 
collaborating labs through a collaborative effort by monitoring glucose-stimulated insulin 
secretion in live animals.
94
  KO animals of both sexes showed enhanced insulin release 
two minutes after an i.p. glucose challenge compared to control (Figure 4.7A).  
Additionally, KO mice showed lower glucose excursion after i.p. injection of glucose, 
consistent with increased glucose tolerance (Figure 4.7B).  The results are consistent with 




Figure 4.7. Early-phase insulin release and glucose tolerance were improved in pancreas ObR-KO 
mice compared to ObRlox controls.  (A) Plasma insulin levels after injection of glucose (3 g kg
-1
 body 
weight) in 6-month old mice of both types.  (B) Blood glucose levels after injection of glucose (2 g kg
-1
 
body weight).  For all plots, *P < 0.05 compared to ObRlox controls and n ≥ 6.  Error bars are ± 
SEM.  Reproduced from reference 94. 
 
To assess if the observed increase in acute insulin release (Figure 4.7A and Figure 
4.2) and improved glucose tolerance (Figure 4.7B) in KOs could provide protection from 
the effects of diet induced obesity, mouse types were fed with a high fat diet (HFD).  
After 12 weeks on HFD, both mouse types showed similar weight gain and insulin 
resistance compared to control groups on normal chow (data not shown).  Interestingly, 
KO animals showed impaired glucose tolerance resulting from decreased acute in vivo 
insulin response to glucose compared to ObRlox controls (Figure 4.8A & B).  
Additionally, KO animals showed significantly reduced islet mass compared to controls 
after HFD (Figure 4.8C).  These results suggest that KO animals may be more susceptible 





Figure 4.8. Effects of diet-induced obesity on islet function and size.  (A) Glucose tolerance test 
results for 4-month-old male mice of both types on regular chow (Chow) or high fat diet (HFD) for 
12 weeks. *P < 0.05 for KO versus ObRlox mice both on HFD, n = 5; †P < 0.05, ‡P < 0.01 for KO 
mice on HFD versus KO mice on Chow, n = 5 (KO) or 3 (Chow).  (B) Change in insulin levels after 
glucose injection (3 g kg
-1
 body weight) in mice on HFD for 12 weeks. ¶P = 0.07; n = 4.  (C) Left: 
Hematoxylin and eosin staining in representative pancreas sections of mice on HFD for 12 weeks. 
Scale bars = 100 μm. Right: Mean islet area from ≥ 10 islets from 5 mice for each genotype.  Error 
bars are SEM.  **P < 0.01 versus ObRlox.  (D) Plot comparing averaged insulin secretion rates from 
islet data presented in Figure 4.4 (only treatments without the presence of leptin).  *P < 0.05.  Error 
bars are ± SEM.  (A), (B), and (C) are reproduced from reference 94. 
 
Results from isolated islet FFA incubation experiments complement these 
observations.  A plot comparing average insulin release (from data presented in Figure 
4.4) from each islet type for BSA and FFA incubations is shown in Figure 4.8D.  Insulin 
release from KO islets decreased by 48% and 54% for 8 and 15 mM glucose stimulations, 
respectively, after FFA incubation.  In comparison, ObRlox control islets decreased by 
only 21% and 37%, suggesting that islets from animals with pancreas ObR deletion may 
be more susceptible to FFA incubation-induced effects.  These results indicate that islets 
developed without leptin signaling may have inferior lipid regulation mechanisms 
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compared to control islets and thus are more susceptible to FFA-induced lipotoxic 
effects. 
Proposed Mechanisms of Leptin Effects on Islets.   Islet types were 
investigated with immunohistochemical analysis (by collaborating researchers) to probe 
if disruption of leptin signaling affects islet morphology.  KO islets were found to have a 
2-fold increase in β-cell mass secondary to an increase in size, but unlikely due to 
enhanced mitosis or altered β-cell apoptosis (data not shown).  Western-blotting analysis 
of islet lysates showed increased phosphorylation of PKB/Akt at Ser473 (p-Akt), p70 S6 
kinase at Thr389 (p-p70S6K), and FoxO1 at Ser256 (p-FoxO1) in KO islets by 2.1-, 1.3-, 
and 4.3-fold, respectively, compared to ObRlox islets (Figure 4.9A).  p70S6K and 
PKB/Akt are important for determining β-cell size and survival, respectively,
148-150
 







Figure 4.9. Increased expression of insulin signaling proteins in islets from KO mice.  (A) Western 
blot analysis of islet lysates for p-Akt (Ser473), Akt, p-p70S6K (Thr389), p70S6K, p-FoxO1 (Ser256), 
FoxO1, and α-tubulin as a control. The relative expression of p-Akt, p-p70S6K, and p-FoxO1 
normalized to each total protein is shown in the plot on the right. *P < 0.05 versus ObRlox; n ≥ 4.  (B) 
Western blot analysis for p-PTEN, PTEN, and α-tubulin. The relative expression of p-PTEN in KO 




A recent report showed phosphatase and tensin homolog (PTEN), a negative 
regulator of the PI3K/Akt pathway, to be regulated by leptin in pancreatic β-cells.
151
  To 
investigate the effects of inhibited leptin signaling on phosphatase activity, western-
blotting analysis for PTEN was performed on islet lysates.  Results in Figure 4.9B show a 
mild upregulation of PTEN phosphorylation (p-PTEN) in KOs compared to ObRlox 
controls with no difference in total PTEN expression.  This enhanced PTEN 
phosphorylation in KOs may indirectly increase signaling in the PI3K/Akt pathway in 




In addition to these proposed roles in islet growth and development, leptin is 
thought to protect islets from lipid overload and nonoxidative metabolic products of fatty 
acids by increasing β-oxidative metabolism of surplus fatty acids and reducing 
lipogensis.
152,153
  Prior studies showing that expression of ObRs in islets of Zucker 
diabetic fatty rats decreased accumulation of lipid content illustrate this potential role for 
leptin in lipid metabolism and storage.
152
  The islet secretion results shown in Figure 4.4 
and in vivo results from Figure 4.8 also suggest a role for leptin in regulating lipid 
metabolism in islets.  It is appealing to hypothesize that the decreased in vivo secretory 
response and islet size in KO animals after HFD is due to secondary effects of lipid 
overload caused by inhibited leptin signaling.  An outline summarizing this possibility is 
illustrated in Figure 4.10.  However, further investigation into specific connections 
between leptin signaling, lipid metabolism, and islet growth factors are needed. 
 





Further experiments probing mechanisms behind leptin action on islets were 
performed by observing insulin release stimulated with sulfonylurea and GLP-1.  
Sulfonylurea, a class of drug that stimulates insulin release through the direct action of 
closing KATP channels, is commonly used to probe KATP channel-independent 
mechanisms of insulin release.
154,155
  Results showed that while stimulation of both types 
of islets with glibenclamide and low levels of glucose yielded similar secretion rates 
(though slightly higher for KOs), addition of higher levels of glucose elicited 
significantly more secretion from KO islets compared to ObRlox controls.  These results 
are consistent with the coupling of leptin signaling pathways with glucose dependent, 
KATP channel-independent mechanisms of insulin release.  However, further biochemical 
analyses probing regulation of known signaling intermediates are warranted. 
The incretin hormone GLP-1 is known to be a potent regulator of glucose-
stimulated insulin secretion,
147
 though the precise mechanism of action has yet to be 
defined.
156
  Recent studies aimed at elucidating GLP-1 action on β-cells have revealed 
multiple potential signaling pathways,
157
 with one report describing the possibility of 
GLP-1 signaling having the ability to overcome leptin-inhibited insulin secretion in 
islets.
158
  This report suggests the role of leptin is primarily a dampener of basal insulin 
release during fasting and not an acute governor of insulin secretion.  In this model, the 
amounts of inhibition that leptin produces can be easily overcome by nutrient and incretin 
signals (e.g. GLP-1) accompanying feeding.  Results presented in this chapter correlate 
with this model by illustrating a reversal of the effects of leptin on glucose-stimulated 
insulin release by the addition of GLP-1 (Figure 4.6). 
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High Throughput Single Islet Analysis on a Microchip.   The 15-islet 
microchip described in Chapter 3, which allowed for fast and high throughput monitoring 
of insulin release (assays every 10 s) on the single islet level, was used to collect all 
insulin secretion data presented here.  The chip allowed for faster collection of islet data 
(compared to single- and four-sample devices) and ease of use for islet stimulation with a 
variety of insulin secretagogues and drugs of interest.  Specifically, islets were perfused 
with combinations of glucose, leptin, palmitic acid, glibenclamide, and GLP-1 in BSS.  
Rate of experiment competition was maximized through the simultaneous collection of 
multiple data sets by loading the chip with two different types of islets (e.g. one set of n = 
7 ObRlox and another of n = 8 KO) and treating all of them with the same perfusion 
buffer.  The collected single islet insulin secretion traces could be averaged together to 
produce the types of plots shown throughout this chapter (typically used for islet type and 
treatment comparisons) and also used for direct comparison of single islet behavior. 
Single islet comparisons allow additional information to be extracted from 
experiments through observations of the insulin release dynamics of single islets.  While 
traditional batch islet experiments hinder this type of evaluation, monitoring single islet 
insulin release in parallel allows these comparisons to be made.  As an example of this 
type of analysis, the individual islet traces that comprise KO averaged data in Figure 4.4 
(8 mM glucose stimulation, FFA versus BSA, no leptin) are shown in Figure 4.11.  After 
48 hr treatment with cell media supplemented with BSA, 60% of KO islets showed 
pulsatile insulin release after stimulation with 8 mM glucose.  In contrast, no islets treated 
with palmitic acid showed an oscillatory response.  These data suggest that lipotoxic 
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effects on islets may inhibit mechanisms controlling pulsatile insulin release (shown to be 
important in insulin action on target tissues),
159,160
 in the absence of leptin signaling.  
 
Figure 4.11. Insulin secretion traces from individual KO islets after incubation in fatty acid-free BSA 
(BSA) or 0.5 mM palmitic acid (FFA).  Bars over plots (only in top left of each group) indicate 
perfused glucose concentration (low bar = 3 mM, high bar = 8 mM). 
 
 
A total of 28 data sets consisting of 153 single islet experiments were collected 
with an over 25,000 insulin assays performed (a cost of over $125,000 using traditional 
ELISA kits).  A total of 14 non-consecutive days were spent running experiments (not 
including preparation, islet isolations, data analysis, etc.).  In contrast, using a single-
sample microchip to perform these studies would have required 53 days of experiments 
(assuming the completion of 3 islets a day which may not always be possible).  These 
time savings further illustrate the advantages in using this device for high-throughput 




 A developed tool for monitoring insulin release from 15 single islets in parallel 
was used to investigate the effects of leptin signaling in islets.  Experiments involved 
monitoring insulin release from single islets exposed to glucose, leptin, palmitic acid, 
glibenclamide, and GLP-1.  An advantage in using the 15-sample device for islet studies 
was illustrated by the comparison of single islet secretion dynamics (Figure 4.11), an 
evaluation that cannot be performed with typical batch islet experiments in which 
secretion is measured from 20 or more islets grouped together.  The results presented in 
this chapter suggest interaction of leptin signaling with FFA, glibenclamide, and GLP-1 
stimulation of islets; however, further studies are needed to elucidate pathways 






IMPROVED QUANTIFICATION IN ON-CHIP INSULIN SAMPLING USED FOR 




The ability to monitor insulin release from single islets holds potential to be a 
valuable tool in diabetes research.
49,87,92,93,125
  In techniques for single islet secretion 
analysis, islets are commonly perfused with stimulant followed by offline analysis of 
perfusate for cellular secretions.  Islet analysis microchips,
49,92,93
 including the device 
presented in Chapter 3, offer an integrated online method for measuring insulin release.  
On these chips, an electrophoresis-based immunoassay for insulin is coupled to 
hydrodynamic perfusion flow for islet stimulation.  Individual islets loaded into these 
chips were perfused by passing flow through a perfusion chamber that was open to 
atmosphere.  The majority of sampled insulin would flow out of the chamber while only a 
small portion of insulin from the side of the chamber was sampled by electroosmotic flow 
(EOF), as illustrated by Figure 5.1A & B.  With this type of perfusion, obtaining a 
representative sample depends on the ability to extract insulin from a localized region of 
the islet that is representative of total insulin released.  An additional disadvantage to 
sampling controlled by EOF is that changes in sampling buffer composition (e.g., ionic 





Figure 5.1. Illustrations of EOF-based islet sampling and heterogeneous insulin secretion from an 
islet.  (A) Side-view of islet perfusion chamber holding an islet (not to scale).  The majority of 
perfusion flow and secreted insulin flows into the fluidic reservoir positioned above the islet.  
Grounding of the reservoir and application of a negative potential downstream on the chip allows 
EOF to be used to sample released insulin.  (B) Top-view of EOF-based insulin sampling.  Sampled 
perfusate is mixed with antibody and labeled-antigen (also controlled by EOF).  (C) Imaging analysis 
of Zn
2+
 release (co-secreted with insulin) from an islet.  In the series of pseudocolor images, higher 
local intensity indicates an increase in Zn
2+
 concentration.  Comparison of release from the regions of 
interest outlined in the far left image show different intensities indicative of different localized insulin 
release rates (lower plot).  (C) is reproduced from reference 162. 
 
 
Characterization of flow through this type of sampling chamber has suggested the 
potential for non-uniform insulin sampling.  In these experiments (presented later in this 
chapter), confocal fluorescence images of an islet in a sample chamber perfused with 
fluorescein showed nonuniformity in concentration of perfused agent during the steady 
state.  These results suggest that there may be variations in the concentration of stimulant 
around the islet during an experiment, in turn causing variation in the amounts of insulin 
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release from local sites on the islet surface.  (A recent study showed localized Ca
2+
 flux, a 
precursor to insulin release, resulting from a partially stimulated islet).
161
  Though this 
pattern of perfusion flow around the islet (and variation of stimulant) is likely to be 
observed in many cell perfusion apparatuses, the sampling of insulin from only one area 
or side of the islet may not yield a representative sample of total insulin release.  
Furthermore, there is evidence to suggest that that insulin release from islets incubating in 
glucose is not spatially homogenous as shown by Figure 5.1C in which a Zn
2+
 reactive 
dye is used to indirectly measure insulin release around and islet.
162
  A system in which 
all cellular secretions are collected will yield a more quantitative sample representative of 
single islet secretion and also maintains the potential to be applied to other cells-on-chip 
systems. 
 Work presented here is aimed at redesigning portions of the 15-islet chip 
presented in Chapter 3 to allow collection of all insulin released by islets for more 
uniform sampling.  In this chip design, islets are housed in reversibly sealed chambers 
(facilitating addition and removal of samples) through which perfusion flow is passed.  
All of the stimulated insulin release from the islet is then pushed out of the chamber and 
through a channel leading to the assay portion of the chip.  The capillary electrophoresis 
(CE)-based immunoassay for insulin
90,91
 demonstrated with other islet microchips was 
used for quantification of insulin. 
The new chip was tested by quantitatively monitoring single islet secretion 
dynamics, specifically biphasic and pulsatile insulin release from islets in parallel.  After 
successful characterization and testing, preliminary experiments investigating pulsatile 
insulin release
163,164
 were performed.   Studies included characterizing oscillation 
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frequencies of islets from individual animals, complementing a prior study showing that 
individual outbred mice have an intrinsic Ca
2+
 flux oscillatory frequency (e.g. islets from 
a single animal show Ca
2+
 flux with the same period).
126
  Additionally, preliminary 
experiments probing the effects of free fatty acid (FFA) induced lipotoxicity on pulsatile 
insulin release were performed.  Results from these studies illustrate the usefulness of 
high throughput methods for collecting single islet data.  
 
Experimental Section 
Chemicals and Reagents.  Unless otherwise noted, all reagents were from Fisher.  
Tricine was from MP Biomedicals (Aurora, OH).  Collagenase type XI, insulin, EDTA, 
fluorescein, and Tween 20 were from Sigma (St. Louis, MO).  Cell culture reagents were 
purchased from Invitrogen (Carlsbad, CA).  Fluorescein isothiocyanate-labeled insulin 
(FITC-ins) was obtained from Molecular Probes (Eugene, OR), and monoclonal antibody 
(Ab) to human insulin was from Biodesign International (Saco, ME).  
Poly(dimethylsiloxane) (PDMS) was purchased from G.E. Silicones (Waterford, NY).  
All solutions were made with 18-MΩ deionized water from a Millipore (Bedford, MA) 
Milli-Q filtration system and filtered with 0.2 μm nylon syringe filters. 
Buffer for immunoassay reagents was 50 mM NaCl, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 20 mM tricine, 0.1% (w/v) Tween 20, and 0.7 
mg mL
-1
 BSA, adjusted to pH 7.4.  Balanced salt solution (BSS) used as a physiological 
buffer for islets experiments consisted of 125 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 
2.4 mM CaCl2, 25 mM tricine, and 0.7 mg mL
-1
 bovine serum albumin (BSA), adjusted 
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to pH 7.4 with NaOH.  Separation buffer consisted of 20 mM NaCl and 150 mM tricine, 
adjusted to pH 7.4. 
Microfluidic Chip Fabrication.  The microchip design illustrated in Figure 5.2A 
was fabricated using previously described wet-chemical etching techniques.
49
 Channels 
were etched to 15 μm deep in borofloat glass with hydrofluoric acid solution.  Access 
holes to channels were drilled with 360 μm diameter (Tartan Tool Co., Troy, MI) and 1 
mm diameter drill bits (Euro Tool Inc., Grandview, MO).  The four perfusion inlet 
connectors were from Upchurch Scientific (Oak Harbor, WA) and the remaining fluidic 
reservoirs were made in-house from polytetrafluoroethylene (PTFE) tubing cut to length.  
PTFE reservoirs were attached to the chip with epoxy (E-6000, Eclectic Products, Inc., 




Figure 5.2. Channel design, images, and illustrations of key portions of a microfluidic chip for 
monitoring insulin secretion from 15 pancreatic islets.  (A) The channel network of the entire device.  
Black lines represent 15 µm deep microfluidic channels, and fluidic reservoirs are depicted with 
circles (color coded for clarity).  Operation of the chip is described in the Experimental section.  (B) 
Brightfield image of the detection area taken with a CCD camera.  Imaged area was 400 x 400 µm
2
.  
Flow from 15 separation channels enter the center portion of the chip before flowing out through a 
single waste channel.  (C) Side-view representation (not to scale) of an islet perfusion chamber.  Islets 
are loaded into the islet chamber with physiological buffer and then sealed with a PDMS plug under 
a stereomicroscope.  Perfusion buffer flows over the entire islet and pushes all secreted insulin into 
the sampling channel.  (D) CCD image of an on-chip flow-split that allows the fast flowing insulin 
sampling stream to be compatible with the slower flow of EOF-driven immunoassay reagents.  
Arrows indicate direction and relative magnitude of flow. 
 
 
Microfluidic Chip Operation.  The microchip consists of 15 channel manifolds 
capable of CE-based immunoassays for continuous monitoring of insulin release from 
pancreatic islets.  Flow through the radially designed separation channels converges at a 
common point to facilitate parallel fluorescence imaging detection (described later).  
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Electrical connections to the chip were made with a chip-electrode interface built in-
house.  Two separate high voltage power supplies (CZE1000R, Spellman High Voltage 
Electronics, Hauppauge, NY) were used to apply potential to the waste reservoirs (-HV1 
and -HV2) and a single high-voltage relay (Kilovac, Santa Barbara, CA), controlled by a 
LabVIEW program, connected the gate reservoirs to ground. 
Pancreatic Islet Loading and Sampling of Insulin.  In contrast with previous 
immunoassay chips,
49,93
 the device presented here performs islet perfusion, sampling, and 
introduction of secreted insulin to the on-chip assay entirely with hydrodynamic flow.  
The use of hydrodynamic flow for these functions was found to improve insulin sampling 
efficiency and microchip reproducibility when used with various perfusion buffer 
compositions.  Flow from a pressurized vial of perfusion buffer was split four ways with 
a five-port manifold before entering the chip where each stream was split again before 
reaching perfusion chambers.  Chambers on the chip were heated to 37 ºC by a heating 
strip (Minco, Minneapolis, MN) positioned beneath the chip. 
For analysis, islets were housed in perfusion chambers on the chip that were 
sealed with PDMS plugs (Figure 5.2C).  PDMS plugs could be removed so that islets 
could be taken out after experimentation and the chip could be reused.   Care was taken to 
not damage the islets when sealing the chamber, and islets were checked for visible 
damage after every experiment.  Plugs were fabricated by puncturing a thin slab of 
PDMS with small bore blunted-tip stainless steel tubing (20 gauge).  The resulting plugs 
were cut to length with a scalpel under a stereomicroscope. 
Islets were perfused at 500 nL min
-1
 with buffer that could be switched to apply 
different glucose concentrations or test compounds as desired.  The pressure at the islet 
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chamber associated with this low flow rate was not sufficient to break the reversible 
PDMS-glass seal.  A low pressure drop in the islet chamber is also advantageous for 
maintaining islet heath.  A perfusion flow rate of 500 nL min
-1 
is too high for downstream 
operations such as mixing with immunoassay reagents; therefore, a flow-split was added 
to the design (Figure 5.2D) so that only ~3.5 nL min
-1
 was passed to the assay region on 
the chip. 
Insulin Secretion Assay and Calibration.  The inclusion of hydrodynamic 
sampling to the 15-islet chip did not produce significant changes in performance 
compared to the chip presented in Chapter 3, and thus no major changes were made to the 
previously described immunoassay operation.  Briefly, FITC-ins and Ab reservoirs (filled 
with FITC-ins and Ab in immunoreagent buffer, respectively) were grounded while -4 
kV was applied to the waste (-HV2) reservoir allowing the sampled insulin stream to mix 
and react with the immunoassay reagents while flowing through the serpentine-shaped 
reaction channels.  0.5 s injections onto the radially-aligned separation channels were 
made at 9.5 s intervals using an on-chip flow-gating injector.  Injected plugs were 
separated by CE while traveling towards the center portion of the chip where 
fluorescence detection was performed. 
Fluorescence Detection and Data Analysis.  Multiplexed fluorescence detection 
was performed as previously described in Chapter 3.  Briefly, fluorescence imaging of 
the detection area was performed with a 20x objective lens on an inverted epi-
fluorescence microscope (IX71, Olympus America, Inc., Melville, NY) with a Xe arc 
lamp (Sutter Instrument Company, Novato, CA) and electron-multiplying CCD camera 
(Hamamatsu Photonic Systems, Bridgewater, NJ).  A sample brightfield image of the 
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detection area taken using this setup (Figure 5.2B) shows all 15 separation channels and 
the common waste channel within the imaged region. 
Series of images capturing the fluorescent migrating bands were collected ~28 
Hz, stored, and analyzed with SlideBook software (Intelligent Imaging Innovations, Inc., 
Denver, CO).  After the collection of images, fluorescence intensities from regions of 
interest drawn within each separation channel were used to produce parallel 
electropherograms.  Comparison of peak heights from separated FITC-ins:Ab and free 
FITC-ins was used to quantify the amount of insulin introduced to each channel network.  
Calibration was performed by monitoring bound-to-free ratios (B/F) of separated 
fluorescent products while introducing insulin standards into the chip without the 
presence of islets, allowing B/F values to be assigned to specific insulin concentrations.  
Limits of detection (LODs) down to 0.5 nM insulin were calculated, which was sufficient 
for single islet studies. 
Isolation of Murine Islets.  Pancreatic islets were isolated from 20 to 30 g male 
CD-1 mice as previously described.
108
  After isolation, islets were incubated at 37 °C and 
5% CO2 in RPMI cell culture media supplemented with 10% fetal bovine serum, 100 
units mL
-1
 penicillin, and 100 μg mL
-1
 streptomycin.  Islets were used 1 – 6 days after 
isolation.  Islets chosen for experiments were of average size (100 – 200 μm diameter) 
and with an intact membrane.  For studies involving monitoring islet oscillations from 






Results and Discussion 
Characterization of Islet Perfusion.  In previously used chips, individual islets 
were perfused by passing flow through an islet chamber that was open to the atmosphere 
and continuously sampled by EOF.  To evaluate the perfusion system, step changes of 
fluorescein were made in the perfusion line while monitoring the islet chamber with 
scanning confocal fluorescence microscopy.   Figure 5.3A shows a confocal image of an 
islet being perfused at 600 nL min
-1
 with 500 nM fluorescein in BSS.  Panels B and C in 
Figure 5.3 demonstrate the time scale on which fluorescein is washed into and out of the 
islet chamber, respectively.  With the islet present, some nonuniformity in concentration 
of perfused agent is observed during the steady state (see Figure 5.3A and different 
curves in B and C).  Similar experiments in which no islet was present in the islet 
chamber showed no change in fluorescence intensity throughout the entire access hole 
(data not shown).  The “shadowing” effect of the islet is likely to occur with most 
perfusion systems (i.e., cells in a tube or on a plate) with flow from one direction.  This 
suggests that there may be variations in the concentration of stimulant around the islet 
that may cause dissimilarities in the amounts of insulin released into local areas around 





 Figure 5.3. Confocal imaging analysis of islet perfusion.  (A) Confocal image of islet during 
the perfusion of 500 nM fluorescein into the access hole.  Black arrows indicate direction of perfusion 
and sampling fluid flow.  Regions of interest described in parts (B) and (C) are indicated with broken 
lines.  (B) Plots of fluorescence intensity versus time for each of the outlined regions of interest 
during the introduction of fluorescein into islet access hole.  The start of the pressure driven 
perfusion was at t = 0 min.  Data were collected at 2 Hz.  (C) Fluorescence intensity for each region of 
interest during the perfusion of non-fluorescent BSS, flushing out the previously used fluorescein.  
Reproduced from reference 49. 
 
Improved Sampling of Secreted Insulin.  While electrophoretic sampling of 
insulin was found to be useful with single, four-, and 15-islet chip designs, the 
disadvantages associated with potential biased insulin sampling justified redesigning of 
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islet perfusion.  When sampling insulin electrophoretically, the majority of islet perfusate 
and secreted insulin flows into a fluidic reservoir positioned above the islet and only a 
small portion of insulin near the sampling channel continues towards the assay portion of 
the chip.  Depending on the exact location of the islet within the chamber, its proximity to 
the sampling channel, and variation in insulin release across its surface, there is potential 
for sampling different amounts of insulin from islets that have the same overall secretion 
rate.  Although islets used in experiments are size-matched (and should thus secrete 
insulin at similar rates), these factors will increase variability across islets. 
The redesigned sampling portion of the chip, shown in Figures 5.2C and D, 
consists of islets sealed into chambers using removable PDMS plugs.  By sealing islets 
into the chambers while perfusing them with glucose, all of the insulin released from the 
islet is pushed out of the chamber and moved towards the assay.  However, as sampling 
flow coming from the islet chamber is flowing too fast (500 nL min
-1
) to be appropriately 
mixed with immunoassay reagents controlled by EOF, an on-chip flow-split was 
incorporated into the design (Figure 5.2D) to pass only ~3.5 nL min
-1
 of perfusion to the 
assay. 
Before the insulin sampling stream enters the flow-split (with the sampling 
channel emerging from one side as shown in Figure 5.2D) it was imperative that 
perfusate be adequately mixed to avoid bias from laminar flow segregation of secreted 
insulin (i.e., sampled insulin needs to be of uniform concentration across the channel 
before being split).  To determine the appropriate length of channel between islet 
chamber and flow-split that allowed for complete mixing of sample by lateral diffusion, 
the distribution of FITC-ins across two laminar streams was imaged at various points on a 
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straight microchannel with the same dimensions as those used on the 15-islet chip 
(summarized in Figure 5.4).  It was found that laminar flows of 50% FITC-ins solution 
and 50% buffer flowing at a combined rate of 500 nL min
-1
 mixed completely via 
diffusion at a point ~0.6 cm downstream of the convergence point.  To allow mixing of 
insulin leaving the islet chamber, 2.4 cm (a length four-times what was needed for two-
stream mixing) of channel was used to link the islet and flow-split portions of the chip. 
 
Figure 5.4. Summarized setup and results for determining appropriate length of channel between 
islet and flow-split allowing adequate sample mixing.  Black lines in the figure represent a 
microfluidic channel design (mixing tee) and arrows indicate direction of flow.  Solutions of BSS and 
FITC-ins in BSS were mixed on the chip (shown by the lower fluorescence CCD image) by flowing 
both solutions at 250 nL min
-1
 with a syringe pump.  An image taken 0.6 cm from the mixing tee 
(upper expansion) shows complete mixing of the two streams.  Line-scan data (upper right) taken 
from the dotted line drawn on this image confirms complete mixing. 
 
Another advantage of using hydrodynamic flow for sampling is that it allows 
assay performance to be independent of buffer compositions (e.g. ion concentration or 
other additives) that may affect EOF.  The use of different buffers may be of interest for 
performing experiments using various islet treatments or different biological samples.  
When sample flow is controlled by EOF, a change in sample buffer composition may 
result in different sample/reagent mixing ratios on the chip, potentially requiring reagent 
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concentrations to be modified with every buffer for an optimized assay.  A chip that uses 
hydrodynamic sample introduction would be able to maintain a constant sample/reagent 
mixing ratio regardless of buffer composition.  This ability was demonstrated by 
comparing observed mixing ratios in both an EOF-controlled sampling chip and a 
pressure-controlled sampling chip using a variety of perfusion buffers.  For this 
experiment, each buffer was spiked with FITC-ins and perfused into an operating chip 
while the mixing point was monitored with fluorescence imaging.  Mixing ratios were 
determined using fluorescence intensity of the perfused buffer before and after it was 
mixed with immunoassay reagent buffer.  Results are shown in Figure 5.5.  As indicated 
in panel A, mixing varied significantly across the tested buffers for EOF-controlled 
sampling.  Results from the pressure-driven sampling chip (Figure 5.5B), however, show 







Figure 5.5. Comparison of online reagent mixing ratios on electrophoretic- and pressure-sampling 
chips with varying perfusion buffer compositions.  Abbreviations are as follows: KRB, krebs ringer 
buffer; RPMI, RPMI cell media (from Invitrogen); BSS, balanced salt solution; HBSS, Hank’s 
balanced salt solution; aCSF, artificial cerebrospinal fluid; DPBS, Dulbecco’s phosphate buffered 
saline; HEPES, HEPES buffered saline.  Data are averages of the measured mixing ratio at three 
time points, measured 2 min apart from one another.  Error bars are ± 1 standard deviation. (A) Plot 
comparing sample/reagent mixing ratios obtained using electrophoretic sampling.  (B) Plot showing 
mixing ratios obtained with the same buffers as in (A) using pressure-driven sampling. 
 
 
Characterization of Hydrodynamic Sampling Chip Performance.   
Characterization of islet perfusion and sample transport across the device was performed 
by perfusing BSS spiked with 100 nM FITC-ins into an operating device and taking 
fluorescence images at various positions of interest.  These experiments are important as 
a potential disadvantage of using hydrodynamic flow (vs. EOF) for sampling is the 
increased dispersion of sample as it is transported across the device causing a decrease in 
effective temporal resolution.  Results from these experiments are shown in Figure 5.6.  
The upper plot, produced by monitoring the fluorescence intensity of an islet chamber 
(with a loaded islet), shows a rise time (10% - 90%) of 3.5 s.  This suggests the capability 
of fluid exchange and sampling of all insulin secreted by an islet within this time.  The 
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bottom plot was produced from images taken at the injection cross and shows an overall 
delay time of 153 s and a maximum response time of 22 s for the chip (this analysis 
included perfusion dispersion prior to reaching the islet chamber).  These times were 
verified by monitoring B/F on the device after a step-change in perfused insulin standard 
concentrations (data not shown).  This response time is similar to what was observed with 
electrophoretic sampling (~25 s).
49
 With the electrophoretic sampling design, however, 
the rise time was mostly a result of slower fluid exchange in the islet chamber rather than 
dispersion of sample in transit.  A response time of 22 s was adequate for monitoring 





Figure 5.6. Illustration of a single network of the 15-sample chip with flow characterization plots 
from throughout the device.  Fluidic reservoir abbreviations as follows: P, perfusion inlet; I, islet 
chamber; S, flow-split; F, FITC-ins; A, Ab; G, gate; W, waste (-HV1).  The upper plot shows 
fluorescence intensity vs. time produced from images of the islet chamber (with a loaded islet) while 
perfusing FITC-ins in BSS at 500 nL min
-1
.  A CCD image of the point of reagent mixing (middle 
expansion) shows perfusate and immunoassay reagent flows entering the reaction channel (FITC-ins 
is only present in the BSS; FITC-ins and Ab reservoirs contain only immunoassay reagent buffer).  
White lines represent channel walls, and arrows indicate direction of flow.  The lower plot, produced 
from images of the injection cross, shows the delay and response time (10% - 90%) for the device up 
to the separation channel. 
 
Parallel Immunoassay Performance.  Before using the device for islet studies, 
the system was tested with the collection of serial immunoassays with online reagent 
mixing.  Serial electropherograms from single channels on the 15-islet chip collected 





















5.7A and B.  Each separation (five per panel) shows two separated immunoassay 
products: FITC-ins:Ab (bound) and FITC-ins (free).  The change in peak heights 
observed between the two panels was caused by an increase in insulin (5 nM in panel A, 
100 nM in panel B) which shifted the immunoassay product ratio through a competitive 
binding reaction.  Good reproducibility of migration times were observed on a single 
channel (relative standard deviation (RSD) of less than 1% for 5 separations).  Low RSDs 
were also observed for single channel B/F (less than 2.5% for 5 separations). 
 
Figure 5.7. Typical serial and parallel electropherograms obtained with online mixing of 
immunoassay reagents.  Injections were made every 10 s.  FITC-ins bound complex [B] and free 
FITC-ins [F] are labeled accordingly.  (A) Serial electropherograms collected when mixing 50 nM 
FITC-ins, 40 nM Ab, and 5 nM insulin standard.  (B) Electropherograms collected after the 
introduction of 100 nM insulin standard into the same channel used in (A).  RFU values are shown in 
(A) and (B) to allow peak height comparisons.  (C) Serial electropherograms collected in parallel 






Serial electropherograms collected in parallel with all channels on the 15-islet 
chip are shown in Figure 5.7C.  Migration time RSD across the entire chip (< 4%) was 
larger than observed for a single channel, but still acceptable for parallel separations 
controlled by a single injection trigger.  Small migration time variation is important in 
this case since parallel separations can only by performed as fast as they occur on the 
slowest channel.  Averaged B/F RSD across all 15 channels (9.6%) was also larger than 
observed for single channel studies. 
An unexpected advantage of using hydrodynamic sampling can be seen by minor 
improvements in chip performance and assay stability compared to parallel separations 
performed with the 15-islet chip with electrophoretic sampling (Chapter 3, Figure 3.3).  
Lower B/F RSDs for both analyses in a single channel as well as across all 15 channels 
were observed.  Specifically, single channel B/F RSD decreased from ~3.5% to 2.5% for 
5 serial assays and from 6% to 5% for 20 minutes of continuous operation when using 
hydrodynamic sampling.  Additionally, the averaged B/F RSD across all 15 channels was 
reduced from 11.7 % to 9.6 %.  Though minor, it is possible the improvements in assay 
stability are a result of more stable sample introduction flows that are not affected by 
factors such as non uniform channel surface properties or sample and protein adsorption.  
However, as flow through the rest of the chip is still partially controlled by EOF, it is 
enticing to think that a parallel device controlled entirely by hydrodynamic flow may 
show little to no variation between channel networks. 
Parallel Measurement of Insulin Secretion from Pancreatic Islets.  
Functionality of the parallel microchip was tested by simultaneously monitoring insulin 
secretion from multiple individual islets stimulated with glucose.  Two types of secretion 
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experiments were performed: stimulation with a 3 mM to 11 mM glucose step change to 
yield a biphasic response,
103,165
 and continual stimulation of islets with 10 mM glucose to 
elicit oscillatory secretion.
126,166,167
 These types of secretion characteristics have been 
suggested to be critical in governing insulin action on target tissues,
159,160
 and methods 
that can monitor these dynamics hold potential to be valuable tools in diabetes research.   
Insulin secretion plots shown in Figure 5.8A were from islets treated with a step 
change in perfused glucose concentration (3 mM to 11 mM) at t = 3 min.  The figure 
presents plots from 13 islets (from a total of 15) that showed an increased rate of release 
after glucose stimulation from a single experiment with the microchip.  The majority of 
plots show pronounced 1
st
 phase release of insulin followed by a 2
nd
 phase of sustained 
release; however, several islets show oscillatory release or a continual increase in release 
rate.  An average of these plots (panel B) shows a biphasic insulin release profile that is 
characteristic of pancreatic endocrine tissue stimulated with elevated glucose.
103,121
  The 
averaged basal rate of insulin secretion from Figure 5.8B (46 pg min
-1
 at 3 mM glucose) 
is slightly higher than values obtained using the previous 15-islet chip (34 pg min
-1
) as 
well as the four-islet chip (27 pg min
-1
).  The secretion rate after glucose stimulation (160 
pg min
-1 
peak) is also higher than what was observed with electrophoretic sampling, but 
still similar to what other studies using islet perfusion techniques have reported (showing 










Figure 5.8. (A) 13 secretion plots from islets stimulated with a step change in glucose concentration.  
Two islets showed no increase in secretion rate after stimulation with high levels of glucose.  Bars, 
shown only in the upper left plot, indicate glucose concentration (low bar = 3 mM glucose, high bar = 
11 mM glucose).  (B) Averaged plot from 13 single islet traces collected simultaneously with the 15-
sample device.  Average bars, placed every other data point for clarity, are ±1 SEM (standard error 
of the mean). 
 
 
Results from continual exposure to 10 mM glucose are shown in Figure 5.9.  The 
insulin secretion plots in panel A are from six individual islets showing expected pulsatile 
responses, with oscillation periods between one and three minutes.  The distribution of 
oscillation periods from a total of 25 islets treated with 10 mM glucose is shown in 
Figure 5.9B (data taken from two experiments with the 15-islet chip).  Observed 
secretion periods from these islets ranged from 1.25 to 3.25 minutes.  Additionally, 
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several islets showed no oscillations suggesting that pulsatile behavior was either absent 
or too fast to be adequately sampled with the temporal resolution of the device.  Indeed, 
metabolic and intracellular Ca
2+
 oscillations (driving factors in insulin exocytosis) with 
periods less than 10 s have been monitored in islets.
169
  Of the islets studied here, 24% 
either did not oscillate or had oscillations faster than the measured temporal resolution of 
22 s.  The distribution of oscillation frequencies displayed in Figure 5.9B shows a 
bimodal distribution that may suggest the presence of “fast” and “slow” oscillations
163,164
 
(although fast oscillations were not directly observed). 
 
Figure 5.9. (A) Plots from six of 15 islets run simultaneously on the 15-islet chip showing oscillatory 
insulin release.  Islets were stimulated with continuous flow of 10 mM glucose.  (B) Plot comparing 
oscillation periods from a group of 25 islets from 2 mice tested with the 15-sample device over two 
experimental periods.  These data show a bimodal distribution of periods including islets that showed 
no oscillations and islets that oscillated with periods of 1.25 – 3.25 min. 
 
 
Both of the islet studies presented here demonstrate the usefulness of a high 
throughput single islet monitoring system by showing the capability of obtaining 
information on the single entity level as well as data that can be made into averaged plots.  
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Single islet data is important because it gives information pertaining to the dynamics of 
insulin secretion, which can be just as critical as the amount of insulin released.
122
  
Underlying mechanisms behind specific patterns of secretion have not been firmly 
identified and there is much interest in the development of theories explaining the 
fundamental causes of these dynamics and their potential involvement in diabetes. 
Characterization of Pulsatile Insulin Release Frequencies from Individual 
Animals.  To demonstrate the potential utility of the chip for characterizing insulin 
secretion dynamics, pulsatile release from islets from individual mice were examined.  A 
recent study showed that isolated islets from individual outbred mice have a characteristic 
Ca
2+
 flux oscillatory frequency (i.e., islets from one mouse oscillate at specific period 
while islets from another mouse pulsed either faster or slower).
126
  Though mechanisms 
behind oscillating islet behavior are not well defined, these results suggest that mice have 
an intrinsic drive in vivo that maintains similar Ca
2+
 flux oscillations within islets from a 
particular animal.  Studies have shown reduction in amplitude and possibly frequency of 
secretion pulses in diabetic patients,
170,171
 and it is possible that this observed imprinting 
could potentially influence the vulnerability of individuals to developing diabetes.
126
 
However, a direct link between insulin secretion frequency in isolated islets and 
individual mice has not yet been observed (primarily due to insufficient islet secretion 
analysis methods).  Using the redesigned 15-islet microchip, we tested islets from 6 
individual mice for Ca
2+
 flux and insulin release oscillation periods during continual 
stimulation with 11.1 mM glucose.  Ca
2+
 and insulin oscillations were observed under 
conditions reproduced from the previously described study to: i) establish the variability 
observed between animals was real and ii) show these variations in insulin secretion 
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mirrored the individual differences in Ca
2+
 at the single islet level.  Oscillations from 
three mice used in the study are shown in Figure 5.10A, illustrating similar frequencies 
coming from particular mice.  Results summarized by plotting the average of observed 
Ca
2+
 flux and insulin release periods from each mouse (Figure 5.10B and C) show two 
interesting trends: i) islets from single mice showed similar Ca
2+
 and insulin secretion 
frequencies and ii) oscillation periods are noticeably different from mouse to mouse.  
These results agree with the previous Ca
2+
 flux study, and confirm that insulin release 











 flux and insulin release profiles showing oscillatory frequencies that are 
characteristic of individual animals.  (A) Ca
2+
 flux and insulin release traces from islets taken from 
three different mice (labeled accordingly).  Displayed oscillation frequency averages are 9 min 
(mouse 1), 4.5 min (mouse 2), and 15 s (mouse 3).  Periods were calculated using local minimum 
values.  Insulin oscillations from mouse 6 were faster than the measured temporal resolution (22 s) of 
the chip, causing undersampling of secretion dynamics.  (B) Comparison of average Ca
2+
 and insulin 
oscillation periods from each animal.  Data sets are n ≥ 6 islets and error bars are ± 1 standard 
deviation.  (C) Plot of average Ca
2+
 versus insulin for each mouse.  The linear relationship of data 
points suggests good agreement of oscillation frequencies. 
 
Preliminary Investigations into the Effects of Chronic FFA Exposure on 
Pulsatile Secretion.  Experiments probing how long-term exposure to fatty acid 
influences secretory dynamics were performed by monitoring release from islets after 
being exposed to high concentrations of palmitic acid for 48 hours.  Such incubations 





 and inhibited glucose-stimulated insulin secretion.
144
  This effect of fatty 
acids is considered a model of lipotoxicity, a potential mechanism of islet functional 
degradation in type 2 diabetes.
173
 Although chronic exposure to fatty acids has been 
shown to cause a blunted first phase response from islets,
174
 its effects on single islet 
oscillations are not well studied. 
After incubation, islets were subjected to continuous perfusion with 10 mM 
glucose to induce oscillatory behavior while either intracellular Ca
2+
 levels or insulin 
release was monitored.  Results showing three single islet plots from each data set in 
Figure 5.11 (A, Ca
2+
 flux from islets incubated in control media; B, Ca
2+
 flux from islets 
incubated in FFA; C, insulin release from islets incubated in control media; D, insulin 
release from islets incubated in FFA) illustrate that overall Ca
2+
 flux and insulin release 
rates were lower from islets treated with palmitic acid incubation, in agreement with 
previous studies.  However, comparison of averaged insulin secretion (control: 148.72 pg 
min
-1
 ± 26.99; FFA: 112.91 pg min
-1
 ± 33.51) and Ca
2+
 flux (control: 202.14 nM ± 24.77; 
FFA: 167.48 nM ± 20.86) across all islets tested between the two groups did not yield a 
significant difference for either experiment (P ≥ 0.07).  The dynamic recordings shown 
here, however, offer more information regarding the impaired release and show 
association with suppression of oscillatory behavior.  The islets affected by FFA 
incubation (panels B & D) show decreased oscillation amplitude as well as perturbed 
periods (either lacking oscillations completely or having potentially much slower 
oscillations than observed in panels A & C).  These data suggest that FFA-induced 
lipotoxicity in islets can potentially affect mechanisms that control pulsatile secretion, 
possibly including oscillatory glycolysis
175





Furthermore, these results demonstrate the utility of the 15-islet chip for comparing 
single islet pulsatile release and highlight the potential importance of this type of data in 
diabetes research. 
 
Figure 5.11. Effects of long-term FFA islet exposure on pulsatile Ca
2+
 flux and insulin release.  Single 
islet insulin secretion and Ca
2+
 flux were monitored during continuous perfusion of 10 mM glucose 
after 48-hour incubation in RPMI media supplemented with either FFA-free BSA (A & C) or 0.5 
mM palmitic acid (B & D).  Islets incubated in FFA showed little to no oscillatory behavior, while 





 A microfluidic chip for measuring insulin release from 15 isolated pancreatic 
islets with improved sampling was presented.  Characterization of microchip 
111 
 
performance showed a delay time of 153 s and an expected rise time of 22 s for changes 
in insulin levels in the device.  The chip was used to monitor biphasic and pulsatile 
insulin release from islets in parallel.  Additionally, single islet data gathered with the 
device was used to characterize oscillatory secretion frequencies of islets from individual 
animals, showing that pulsatile release was similar between islets from a single animal, 
but different across multiple animals.  Finally, studies aimed at investigating the effects 
of chronic FFA exposure on pulsatile insulin release showed an inhibition of secretion 
dynamics in islets treated with FFA incubation. 
 The microchip presented here allowed collection of high-throughput single islet 
secretion data for investigations of pulsatile insulin release.  Previously reported methods 
of single islet analysis have offered the collection of data in lower throughput formats, 
and are thus not amenable for fast collection the data sets presented here.  For example, 
the insulin secretion data from each mouse presented in Figure 5.10 were collected in a 
single experiment with the parallel chip.  The use of a single sample method to collect 











 Microfluidic devices for parallel analysis of insulin release from single islets of 
Langerhans were developed.  These chips showed a marked improvement over single-
sample devices through the collection of high throughput single islet secretion data while 
minimizing time, effort, and animal sacrifices needed for experiments.  Analyses for 
insulin on chips housing four and 15 islets were made every 6 – 10 s allowing for 
characterization of islet secretion with high temporal resolution.  The increases in islet 
throughput were accomplished by developing chips with multiple microfluidic channel 
manifolds, each capable of performing CE-based immunoassays.  Additionally, these 
chips incorporated multiple CE separation channels, necessitating the use of methods for 
multiplexed fluorescence detection.  Additional advantages over single sample devices 
are found in cost savings.  The cost of reagents used with the 15-islet chip was as low as 
~$0.01 per assay, a substantial improvement over typical ELISA kits that may cost over 
$5 an assay. 
 The first parallel islet microchip was designed for analyzing four samples 
simultaneously.  Separations of immunoassay products were performed on microfluidic 
channels aligned parallel to one another, with multiplexed fluorescence detection being 
performed with a commercial scanning confocal microscope operated in line scan mode 
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(raster scanning a laser spot across the channels).  Assays on this chip were performed 
every 6.25 s, yielding an overall rate of ~38 per minute.  Assay LODs were roughly 10-
fold worse than reported with single sample devices, ranging from 7 – 10 nM insulin.  
Although not as sensitive as previous chips, the 4-islet device was successfully used to 
monitor insulin release from islets in parallel. 
 Improvements in assay sensitivity and throughput were made with a second 
parallel islet chip capable of monitoring 15 islets.  The use of a radial design of 
microfluidic channel networks (separation channels in the center portion of the chip with 
islet perfusion and immunoassay reagent mixing along the outer edges) facilitated this 
increase in performance.  In this design, flow through the separation channels converged 
at a common point in the center of the chip where multiplexed detection was performed 
via fluorescence imaging.  Separations on this chip were performed every 10 s, giving an 
overall immunoassay completion rate of 90 per minute.  This chip was successfully used 
to monitor biphasic insulin release from 15 islets in parallel with reported LODs of 0.5 – 
1 nM insulin (improved over results from the 4-islet chip). 
 After successful testing of the 15-islet microchip, it was used in a collaborative 
study investigating leptin signaling in islets.  The expression of leptin receptors on cells 
in the endocrine pancreas suggests leptin may have direct interactions with islets in 
addition to its well characterized effects on the hypothalamus.  In order to investigate the 
direct effects of leptin on islets, the 15-islet chip was used to monitor insulin release from 
islets from mice modified to lack leptin receptors in only the pancreas.  Experiments 
involved characterizing insulin release under various conditions, including stimulation 
islets with glucose, leptin, glibenclamide, GLP-1, and palmitic acid.  Additionally, the 
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effects of long-term fatty acid incubation on knockout islets were studied.  It was found 
that inhibition of leptin signaling in islets from lean animals enhanced glucose-stimulated 
insulin secretion.  Additionally, an inhibiting effect of leptin on insulin release was 
observed. 
 Further improvements made to the 15-islet chip design were aimed at optimizing 
sampling of insulin released from islets.  In previous assays, insulin was sampled from a 
localized portion of the islet chamber, potentially resulting in variation in the amount of 
measured insulin.  The addition of a sealed islet perfusion chamber allowed all of the 
insulin released by an islet to be pushed out of the chamber and towards the on-chip 
assay.  Modifications of islet perfusion and sampling did not result in any significant 
changes in microchip performance; however, minor improvements over previous 15-iselt 
chip channel-to-channel reproducibility were observed.  It is hypothesized that the ability 
to continuously introduce sample to the assay in a way that is independent of channel 
surface properties yields more stable assay operation.  The improved 15-islet design was 
used to monitor biphasic and pulsatile insulin release from islets in parallel. 
 Studies investigating pulsatile insulin release and Ca
2+
 flux oscillations in islets 
from individual mice were performed.  Results illustrated characteristic oscillation 
frequencies from specific mice, showing that pulsatile release was similar between islets 
from a single animal, but different across multiple animals.  Additionally, preliminary 
experiments investigating the effects of chronic fatty acid exposure on pulsatile insulin 
release showed an inhibition of secretion dynamics in islets treated with FFA incubation.  
These studies, performed with the 15-islet chip, demonstrate the utility of high 




 Multiplexed Single Islet Assay.  The microchips presented in this dissertation 
demonstrated the monitoring of insulin release form multiple islets using parallel 
microfluidic networks for performing assays for insulin.  An additional application for 
parallel separations on a microchip would be a device that performs several different 
assays with perfusate from a single islet.  This would be useful in monitoring other 
indicators of islet behavior besides insulin release, for example, the secretion of 
additional hormones such as glucagon and somatostatin.  Also, amino acid secretions and 
interactions are thought to be involved in islet functions.  Recently, there has been 
specific interest in GABA, glutamate, taurine, and glycine secretions from islets.
177-180
  
The ability to measure amino acids in conjunction with insulin and other hormones would 
provide more thorough characterization of islet behavior. 
 The basis for a multiplexed islet analysis chip would be on-chip islet perfusion 
coupled to several online assays, one for each secretion of interest.  In a possible chip 
design presented in Figure 6.1, islet perfusate is split between two networks for 





Figure 6.1 Possible chip design for simultaneous analysis of secretions from a single islet.  Solid lines 
are channels, and circles (color coded for clarity) are fluidic reservoirs.  On this chip, pressure-
driven islet perfusion and sampling as described in Chapter 5 is used to introduce perfusate into 
assays for insulin, glucagon, and amino acids.  Flow splits illustrated in the design will be designed 
independently to ensure proper sample/reagent mixing for each assay.  Reagent flow will be 
controlled by EOF.  The amino acid analysis will most likely require different reaction time, gating 
flow, and separation potential, and will thus be controlled with separate power supplies. 
 
 
 On this device, the assay for insulin would remain largely unchanged from 
methods described throughout this dissertation.  The presented assay for glucagon would 
also function similarly.  Flow from the islet will mix with fluorescent-labeled glucagon 
and anti-glucagon antibody for a competitive immunoassay.  Assuming separation times 
for this assay are similar to what can be obtained with the insulin assay, injections onto 
separation channels in both assays could be controlled by a single injection trigger (as 
shown in Figure 6.1).  However, since glucagon secretion rates are much lower compared 
to insulin (reports have shown about ten-fold lower),
102,181
 it may be necessary to reduce 
the rate of islet perfusion to allow higher concentrations of glucagon to be introduced into 
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the assay.  Additionally, precise control of pressure-driven sample introduction will allow 
optimization of sample/reagent mixing that is independent of flow leading to other 
assays. 
 The on-chip assay for amino acids will be accomplished through online 
derivatization with an amine-reactive fluorescent dye and subsequent analysis with CE.  
With this type of assay there is the potential for needing longer reaction and separation 
times compared to immunoassays, necessitating that flow be controlled by an 
independent injection trigger and power supply.  Previously measured release of amino 
acids from islets measured in our lab yielded concentrations ranging from 2 to 100 nM. 
Online derivatization of analyte concentrations this low may be difficult to perform, as 
methods that report LODs at this level often utilize serial dilutions post-reaction.
182
  
Though OPA derivatization has been shown to be capable of producing LODs for amino 
acids down to 40 nM on a microchip,
183
 the use of this reaction would require detection 
optics not compatible with the fluorescent tags used in the immunoassay (typically 
FITC).  Amine-reactive dyes that excite and emit at similar wavelengths as FITC could 
provide an alternative for single wavelength detection.
184
  Also, it may be possible to 
couple methods for preconcentration of analyte onto the chip design that have been 
shown to increase the concentration of biomolecules by up to 600-fold before injection 
onto a separation channel.
185
  However, these concentration effects have been observed 
after a process time that lasts several minutes, and thus may significantly decrease 
temporal resolution. 
All of the separation channels for the parallel assays would pass through a single 
detection area for multiplexed fluorescence detection.  Detection would be performed 
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using the inverted epi-fluorescence microscope with EMCCD camera that has been used 
for detection with the 15-islet chip.  As mentioned previously, it would be useful for all 
fluorescent probes used in these assays to have similar excitation and emission 
wavelengths to simplify detection optics.  However, if derivatization components that 
fluoresce at different wavelengths are found necessary to obtain required LODs for the 
amino acid assay, options for dual-wavelength excitation and emission can be explored. 
 Integration of Additional Functions onto Parallel Islet Microchip. Further 
development of the 15-islet analysis chips towards a true lab-on-a-chip device would 
include the integration of fluorescence detection, on-chip pumping, and islet heating. 
 Fluorescence detection on the 15-islet chip was performed using light from an arc 
lamp for excitation.  Though this proved useful for the developed assays, the integration 
of LIF detection onto the device could potentially increase sensitivity and allow the chip 
to be used for additional functions.  Integration of LIF detection into microchips has been 
previously demonstrated through the use of optical fibers and liquid-core optical 
waveguides.
186
  With these chips, laser light is introduced into the device with embedded 
fiber optics and then channeled towards a specific channel for fluorescence excitation.  
Though shown on single-channel devices, parallel on-chip fiber optic LIF detection as 
would be necessary for use with a parallel islet chip has not yet been demonstrated.  
Multiplexed detection using a single laser source would require the splitting of light into 
multiple pathways for parallel fluorescence excitation.  It is possible that a radial design 
of separation channels may not be amenable with this type of excitation given the 
difficulty in directing light between adjacent channels.  However, the collection of 
fluorescence emission from separation channels using fiber optics and waveguides rather 
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than a single objective lens would not necessitate the close proximity of detection points 
on a chip, allowing a redesigned device to include detection points spatially separate and 
more amenable for parallel fiber optic LIF detection. 
 The inclusion of pressure-driven flow for perfusion, sampling, and sample 
introduction into the 15-islet chip design yielded channel-to-channel assays that were 
slightly more reproducible compared to EOF islet sampling (Chapter 5).  It is possible 
that this observed improvement in reproducibility was a result of using a type of flow that 
is not dependent on channel surface properties that may vary across a device.
26
  It is 
possible that using hydrodynamic flow to control all sample and reagent movement and 
mixing could improve assay reproducibility even further.  The introduction of 
hydrodynamic flow driven by on-chip pumps would accomplish this goal while also 
producing a more integrated device.  One method of producing integrated microfluidic 
flow control involves creating peristaltic-style pumps using multi-layer soft 
lithography.
187





 adequate for islet perfusion.  A possible chip design using these pumps 
for islet perfusion and immunoassay reagent flow is shown in Figure 6.2.  It will be 
necessary to create a glass/PDMS hybrid chip as the flexibility of PDMS is required for 
proper functioning of the pumps while glass would still be needed for good CE 
separations.  Alternatively, fluid pumping could be performed on a separate layer of 
PDMS through which flow is channeled for pumping before being introduced into the 
glass channels.  CE separations and fluorescence detection would be performed as before, 




Figure 6.2. Possible chip design for integration of on-chip pumps for control of immunoassay reagent 
and sample flow.  On this chip, fluid from perfusion buffer reservoirs would pass through integrated 
pumps before passing over islets sealed into chambers as described in Chapter 5.  Additionally, flow 
of immunoassay reagents would be controlled by on-chip pumps.  The ability to control perfusion 
and reagent flow rates with these pumps will allow direct missing of islet perfusate, eliminating the 
need for previously used flow splits.  Functioning of the pumps, illustrated in the expansion on the 
right, is based on peristaltic-style pumping creating by timed inflation of control channels placed 
over the flow channel.  It is likely that methods for pressure-driven flow-gating will be needed for 
injections on the device.  Expansion in the figure is reproduced from reference 187. 
 
 
A final improvement to chip design discussed here is the integration of islet 
chamber temperature control.  Currently, heating of islets is performed using an external 
thin film heating strip attached to the underside of the chip.  The use of this type of heater 
presents opportunities for uneven heating across the chip caused by variation in manual 
placement from experiment-to-experiment.  Additionally, this heater does not use a 
feedback loop for temperature control, thus variations in ambient temperature may cause 
fluctuations in islet heating.  Integrating controllable islet chamber heating into the device 
could decrease islet-to-islet heating variation as well as allow for monitoring of islet 
temperature.  Integrated resistive heaters have been used with much success for on-chip 
PCR thermocycling, which requires precise control of fluid temperature.
188,189
  The 
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functioning of these heaters is based on the patterning of conductive heating elements 
onto the device.  Electrical current passed through the elements produces heat, and 
monitoring of temperature can be performed by measuring the resistance of additional 
circuits fabricated into the device that are also heated by the elements.
44,63
  Integration of 
these tools onto a parallel islet chip would require the fabrication of multiple circuits of 
resistive heaters and temperature sensors passing under and around islet chambers to 
allow for heating of the perfusion flow and the islet to 37ºC. 
Parallel Islet Analysis with Segmented Flow. Limitations of the temporal 
resolution of the 15-islet chip were demonstrated in Chapter 5 through the inability to 
reproducibly monitor 15 s secretion events.  The development of a method for improved 
temporal resolution in islet analysis would be a useful improvement enabling the 
observation of fast oscillatory events.  Recently, devices utilizing segmented flow for 
droplet-based assays have shown potential for improvements in temporal resolution.
190
  
In these assays, analyte and assay reagents are mixed in aqueous droplets suspended in a 
mobile oil phase.  The reagents are allowed to react while traveling via pressure-driven 
flow to a detector without dispersion.  The generation of droplets at a frequency of less 
than one second has been demonstrated, suggesting the potential for high temporal 
resolution of islet secretions. 
A potential chip design for parallel droplet-based islet monitoring is shown in 
Figure 6.3.  In this design, perfusate from islets is mixed with reagents for an insulin 
immunoassay and then split into aqueous droplets by forces from a flowing oil phase 
(commonly perfluorodecalin).  Flows of perfusate, antigen, and antibody will be rapidly 
mixed when forming a droplet.
191
  Droplets are pushed through microchannels by 
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pressure-driven flow of oil and the competitive binding reactions are allowed to proceed 
while flowing towards a detector. 
 
Figure 6.3. Possible chip design for droplet-based insulin assays for four islets in parallel.  Black lines 
indicate microfluidic channels, fluidic inlets are color coded for clarity.  Perfusion flow from islets 
sealed into chambers will mix with FITC-ins and Ab before intersecting a stream of perfluorodecalin.  
Shear forces at this intersection will create aqueous droplets containing perfusate and immunoassay 
reagents suspended in oil.  Reactions between immunoassay reagents is allowed to occur during 
transit to a detection zone. 
 
 
 Current work in single-channel droplet-based islet assays in our lab has 
demonstrated fluorescence anisotropy as a potential detection technique.  In this method, 
rotational diffusion of immunoassay products is determined by comparing polarization of 
emission light with that of excitation light.  An advantage to this technique is that no 
separation step is required, and detection can be performed on intact droplets.  However, 
difficulty in developing multiplexed chip-based fluorescence anisotropy may necessitate 
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alternative detection methods.  Additional work in our lab has shown the ability to fuse 
droplets to an aqueous stream for CE separations, allowing a portion sample in the 
droplets to be analyzed by CE-LIF.  Previous work presented in this dissertation has 
shown the capability for fluorescence detection of multiple CE separation microchannels, 
suggesting this method as a possible technique for parallel droplet-based assay detection. 
 Development of Data Analysis Software for Parallel Separations.  The 
creation of a microchip for parallel separations greatly increases the rate at which data is 
collected, resulting in a larger total number of electropherograms to be analyzed.  
Although experimental data is collected in parallel, current limitations in data analysis 
software allow separations to be analyzed in a serial nature only (the currently used 
program was developed for a single channel device).
107
  This requires peak high 
comparisons and B/F values to be calculated individually for each separation requiring a 
large amount of time to produce final insulin secretion plots.  A reduction of time needed 
for parallel islet experiments could be made through the development of software capable 
of analyzing and organizing batches of separation data collected in parallel. 
 Ideally, the developed software would have several basic requirements.  Parallel 
information exported by imaging analysis software must be imported and displayed for 
the user.  Additionally, analysis time could be greatly reduced through batching of serial 
data to allow the user to define peak characteristics only once for each parallel channel.  
Ideal output from the program would be a list of calculated B/F values for each parallel 
channel that would be easily imported into Microsoft Excel for conversion into secretion 
rates.  These advancements would greatly decrease the time needed for data analysis 









 The design and fabrication of a functional microfluidic chip is dependent upon 
several critical factors.  Primarily, fluidic channels and microfabricated structures must 
be designed with the appropriate properties to ensure proper performance (e.g. proper 
fluid mixing, reaction times, separation properties) for a particular application.  These 
designs vary a great deal depending upon the intended function.  There are, however, 
additional factors which can be influential in any chip design that can influence 
fabrication and functioning of microchips.  This appendix will discuss several 
considerations aimed at facilitating chip fabrication that should be made when designing 
a microfluidic chip.  The points discussed will generally pertain to glass chip fabrication 
using standard wet-chemical etching techniques as used to create chips described 
throughout this dissertation. 
 
Channel Etching 
 When designing a photomask to be used for patterning a channel design onto a 
glass substrate (photoresist), it is critical to take the etching properties of glass into 
consideration for proper channel placement.  As illustrated in Figure A.1, the isotropic 
etching properties of wet-chemical fabrication steps produce final channel 
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widths that are wider than what were originally designed on the mask.  Thus, it is 
important to place channels on the mask with enough space between them to ensure that 
they remain independent structures after etching.  Additionally, it is possible that the 
channel width patterned onto the glass substrate (photoresist) will be slightly larger than 
that on the photomask after broadening through UV exposure and photoresist/metal layer 
removal steps.  However, these effects are typically minor in comparison to channel 
etching. 
 
Figure A.1. Illustration of expansion of channel width upon etching.  The isotropic etching produced 
when using wet chemical etching techniques produces trapezoid-shaped channels.  During etching, 
total channel width is increased by a distance equal to two-times the depth of the channel.  It is 
important to remember this channel-widening effect and plan accordingly when designing a 
photomask for microchip fabrication. 
 
 
Access Hole Fabrication 
 Microfluidic chips consisting of enclosed channel networks typically require the 
fabrication of access holes to allow control of fluid within the device.  There are several 
methods for fabricating these access points, including ultrasonic and laser drilling 
techniques that can create holes down to 50 µm in diameter.  However, as these processes 
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can be expensive, it is common in our lab to use a drill press and small diameter 
diamond-tipped drill bit for the manual drilling of holes.  In addition to costing less, this 
method can be less time consuming as it does not require microchips to be shipped to and 
from a service provider.  However, since manual drilling is performed by hand with no 
available micromanipulation for hole positioning, care must be taken in planning for 
adequate space on a chip design to facilitate drilling.  It is advisable that channels on the 
chip are placed far enough away from a drilling point to ensure they are not 
unintentionally damaged in the hole drilling process.  Drilling into glass can occasionally 
cause chipping and cratering of the glass surface.  Thus, it is important that channels 
positioned adjacent to access holes be spaced by an appropriate distance to be protected 
from potential damage.  This appropriate distance is dependent upon the skill of the 
student fabricating the chip, but is typically around several millimeters. 
Additionally, when drilling access holes by hand it is important to design a 
microchip that allows hole placement to be reproducible.  For example, it may be difficult 
to manually drill a hole at a specified position on a straight channel with no markers or 
visual cues for drill bit alignment.  It is often useful to design a chip so that holes are 
drilled at channel intersections (bends, etc.) to allow reproducible alignment and drilling.  
Alternatively, the inclusion of visual markers on a photomask that are nearby to channels 
can serve as a reference point for hole drilling. 
 
Fluidic Reservoir Placement 
 Once access hole drilling and the remainder of microchip fabrication is 
completed, fluidic reservoirs are often placed on the chip surface.  These reservoirs are 
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typically needed for a supply of fluid, collection of flow, or as a flow inlet from another 
device (e.g. syringe pump).  Commercially available reservoirs obtained from Upchurch 
Scientific (NanoPort™) having diameters of nine and 10 mm are typically used in our 
lab.  It is helpful to take desired reservoir position into account when designing a 
photomask by planning for enough space on the chip surface for placement of the 
required number of reservoirs.  This process can be facilitated by drawing circles with the 
same diameters as fluidic reservoirs over a mask design created using AutoCAD to 
ensure there is no overlapping.  Additionally, if high electrical potentials will be applied 
to reservoirs on a chip surface for electrokinetic flow, it is suggested that reservoirs be 
completely separated and have no parts touching to assist with electrical isolation. 
If reservoir sizes other than those available with commercial pieces are required, 
it is possible to manually create reservoirs in-house from a variety of materials.  
Numerous vendors can supply glass or plastic tubing of varying inner and outer diameters 
that can be cut to length and affixed onto a chip surface with epoxy.  This option is also 
more cost effective, as commercial reservoirs can cost up to $6 each while PTFE tubing 
costs about $1.60 per foot (enough for 48 reservoirs). 
 
On-Chip Detection Area 
 As our lab typically utilizes fluorescence detection, this section will pertain to 
considerations for designing a microfluidic chip for use with optical detection.  If 
fluorescence point detection is being performed on a chip, it is helpful to design the width 
of a channel at the detection point to be compatible with the diameter of the excitation 
laser spot to maximize fluorescence excitation and emission.  It may also be useful to 
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include a visual marker in the chip design (close to the detection point) to help with 
reproducible positioning of the laser spot on the chip. 
 One important consideration, especially if developing a parallel chip with 
multiple fluorescence detection points, is ensuring that channel and detection area sizes 
are comparable with the field of view of optics used for detection.  If imaging detection is 
used, optics must be able to produce an image of the entire on-chip detection zone on the 
detector.  Though seemingly straightforward, this can be an important consideration as 
the field of view observed through a fluorescence microscope eyepiece is not necessarily 
the same size as the image collected on a CCD chip though a side port on the same 
microscope.  Also, the etching of glass channels will increase the size of the detection 
area on a chip, possibly affecting the field of view needed for detection. 
An additional consideration in optical detection with microchips is compatibility 
between chip thickness and working distance of a required objective lens.  Generally, 
higher magnification lenses have shorter working distances (aside from special long 
working distance (LWD) objective lenses).  If a certain magnification is required for 
detection, it is advisable to ensure the thickness of the device allows for proper objective 
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